[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 152
1. Bretagnol F, Merrie A, George B, Warren BF, Mortensen NJ: Local excision of rectal tumours by transanal endoscopic microsurgery. Br J Surg; 2007 May;94(5):627-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) allows locally complete excision of rectal tumours and provides an alternative to conventional surgery for benign tumours.
  • The median tumour distance from the anal verge was 8 (range 1-16) cm.
  • Histological examination of carcinomas revealed pathological tumour (pT) stage 1 in 31 patients, pT2 in 17 and pT3 in four.
  • CONCLUSION: TEM is an appropriate surgical treatment option for benign rectal tumours.
  • [MeSH-major] Microsurgery. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Intraoperative Complications / etiology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Patient Selection. Salvage Therapy. Survival Rate. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Surg. 2007 Sep;94(9):1179; author reply 1179 [17701963.001]
  • (PMID = 17335125.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


2. Guillem JG, Chessin DB, Jeong SY, Kim W, Fogarty JM: Contemporary applications of transanal endoscopic microsurgery: technical innovations and limitations. Clin Colorectal Cancer; 2005 Nov;5(4):268-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Transanal endoscopic microsurgery (TEM) is a minimally invasive procedure used to transanally excise select benign and malignant tumors of the rectum.
  • PATIENTS AND METHODS: Thirty-two consecutive patients scheduled for TEM were identified from our prospectively maintained colorectal service database.
  • In addition, a PubMed literature search was performed with use of the key words "transanal endoscopic microsurgery," "TEM," "rectal tumor," and "rectal cancer."
  • RESULTS: Transanal endoscopic microsurgery was performed for rectal adenocarcinoma (n = 17; 53%), adenoma (n = 12; 38%), and carcinoid tumors (n = 3; 9%).
  • Median tumor location was 9 cm from the anal verge (range, 3-15 cm).
  • Reasons for inability to complete TEM included narrow rectal lumen or contour of bony pelvis prohibiting passage of the operating proctoscope into the upper rectum and inability to maintain the proctoscope in the rectal lumen with carbon dioxide insufflation because of the distal location of the tumor.
  • Innovations used in the excision of rectal tumors via TEM included the use of the harmonic scalpel, closure of the rectal defect with an extracorporeal slip knot, and a hybrid approach incorporating TEM and traditional transanal techniques.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoid Tumor / surgery. Colonoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356304.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Sánchez A, Muñoz C, Bujanda L, Iriondo C, Gil-Molet A, Cosme A, Sarasqueta C, Echenique-Elizondo M: The value of colonoscopy to assess rectal bleeding in patients referred from Primary Care Units. Rev Esp Enferm Dig; 2005 Dec;97(12):870-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It is produced mainly because of benign disease originating in the anus and the rectum.
  • Severe disease was encountered in 22 patients (neoplasm, angiodysplasia, and inflammatory bowel disease); 10 patients had polyps, 6 had colorectal cancer, and 6 had inflammatory bowel disease.
  • Out of 63 patients younger than 50 years, 5 had severe disease, all of them in the form of inflammatory bowel disease.
  • CONCLUSIONS: A neoplasm of the rectum and colon in patients younger than 50 years is a rare event.
  • A colonoscopy must be performed in this group of patients to rule out inflammatory bowel disease.
  • [MeSH-major] Colonoscopy. Gastrointestinal Hemorrhage / etiology. Rectal Diseases / complications. Rectal Diseases / diagnosis

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16454606.001).
  • [ISSN] 1130-0108
  • [Journal-full-title] Revista española de enfermedades digestivas : organo oficial de la Sociedad Española de Patología Digestiva
  • [ISO-abbreviation] Rev Esp Enferm Dig
  • [Language] eng; spa
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Goldstein PJ, Cabanas J, da Silva RG, Sugarbaker PH: Pseudomyxoma peritonei arising from colonic polyps. Eur J Surg Oncol; 2006 Sep;32(7):764-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This manuscript describes this disease arising from a benign or malignant colonic polyp.
  • METHODS: From a database of over 1000 pseudomyxoma peritonei patients and colorectal carcinomatosis patients, three cases were identified in which the primary tumor site was a colonic polyp.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Polyps / pathology. Neoplasm Seeding. Peritoneal Neoplasms / secondary. Pseudomyxoma Peritonei / etiology

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16765563.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Hemandas AK, Robson NK, Hickish T, Talbot RW: Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans. Colorectal Dis; 2008 May;10(4):386-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal tubulovillous adenomas identified on fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography scans.
  • METHOD: Of the 110 patients in our PET/CT database, 10 were found to have abnormally high uptake of tracer in their large bowel.
  • CONCLUSION: Benign colonic polyps produce high-intensity focal FDG uptake in large bowel.
  • [MeSH-major] Adenoma, Villous / diagnosis. Adenomatous Polyps / radionuclide imaging. Colorectal Neoplasms / radionuclide imaging. Incidental Findings. Positron-Emission Tomography
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Fluorodeoxyglucose F18. Gastrointestinal Neoplasms / pathology. Head and Neck Neoplasms / pathology. Humans. Lung Neoplasms / pathology. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608754.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


6. Wang Q, Xie R, Zhang QY: [Clinical significance of plasma fibrinogen level in patients with colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2005 Sep;27(9):544-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of plasma fibrinogen level in patients with colorectal cancer].
  • OBJECTIVE: To investigate correlation of plasma level of fibrinogen with clinical stage, depth of invasion and metastasis of colorectal cancer, and its diagnostic and prognostic significance.
  • METHODS: The present study included 229 patients suffering from colorectal cancer and 31 cases with benign colorectal diseases.
  • The tumor markers CEA, CA19-9 and CA72-4 were examined by electrochemiluminescence immunoassay on Roche Eleccsys 2010 analyzer.
  • Tumor makers CA242 and TPS were tested by ELISA.
  • RESULTS: The fibrinogen level was increased in patients with colorectal cancer compared to that in patients with benign colorectal diseases.
  • It increased with the clinical stage and depth of tumor invasion.
  • There were positive correlations of fibrinogen level with tumor makers CEA, CA242 and TPS, but not with CA19-9 and CA72-4.
  • CONCLUSION: Plasma fibrinogen is significantly increased in colorectal carcinoma patients with progression of the disease.
  • [MeSH-major] Adenocarcinoma / blood. Colorectal Neoplasms / blood. Fibrinogen / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. Carcinoembryonic Antigen / blood. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Peptides / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438853.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / CA 242 antigen; 0 / Carcinoembryonic Antigen; 0 / Peptides; 0 / tissue polypeptide specific antigen; 9001-32-5 / Fibrinogen
  •  go-up   go-down


7. Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis; 2010 Sep;25(5):463-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the examined groups of patients with colorectal cancer (CRC, n = 89), benign adenoma (AD, n = 77) and healthy volunteers (controls, n = 99), we measured: vitamins A, C and E in blood plasma, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanine (8-oxoGua) in leukocytes and urine, leukocyte 8-oxoGua excision activity, mRNA levels of APE1, OGG1, 8-oxo-7,8-dihydrodeoxyguanosine 5'-triphosphate pyrophosphohydrolase (MTH1) and OGG1 polymorphism.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Repair / genetics. Deoxyguanosine / analogs & derivatives. Oxidative Stress / genetics
  • [MeSH-minor] Adenomatous Polyps / blood. Adenomatous Polyps / metabolism. Adult. Aged. Aging / genetics. Antioxidants / metabolism. Case-Control Studies. DNA Glycosylases / genetics. DNA Glycosylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Polymorphism, Single Nucleotide / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sex Characteristics. Smoking / adverse effects. Smoking / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534734.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.6.- / 8-oxodGTPase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; EC 6.5.1.- / DNA Repair Enzymes; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


8. Benedix F, Köckerling F, Lippert H, Scheidbach H: Laparoscopic resection for endoscopically unresectable colorectal polyps: analysis of 525 patients. Surg Endosc; 2008 Dec;22(12):2576-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection for endoscopically unresectable colorectal polyps: analysis of 525 patients.
  • However, the high rate of malignant transformation despite initially benign histology continues to be a problem.
  • METHODS: Within the framework of a prospective multicenter observational study, all patients with adenomatous polyps unsuitable for endoscopic removal and with benign histology were investigated.
  • In addition to an analysis of the perioperative course and the definitive histology, the overall and disease-free survival rates of patients with malignant transformation of colorectal adenomas were also calculated.
  • In the elderly patient presenting with comorbidities limited resection aiming to minimize surgical trauma in potentially benign disease may be considered.
  • [MeSH-major] Adenocarcinoma / surgery. Adenomatous Polyps / surgery. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Colectomy / methods. Colonoscopy. Disease Progression. Disease-Free Survival. Female. Humans. Laparotomy / statistics & numerical data. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications / epidemiology. Prospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Tech Coloproctol. 2006 Dec;10(4):303-7 [17115319.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Surg Endosc. 2005 May;19(5):643-9 [15789256.001]
  • [Cites] JSLS. 2005 Jan-Mar;9(1):58-62 [15791972.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1246-9 [11005491.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Surg Endosc. 1996 Jan;10(1):15-8 [8711597.001]
  • [Cites] Surg Endosc. 1997 Mar;11(3):264-7 [9079606.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2006 Jan;20(1):30-4 [16333547.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • [Cites] Arch Surg. 2007 Mar;142(3):298-303 [17372057.001]
  • [Cites] Surg Endosc. 2008 Feb;22(2):506-9 [17704872.001]
  • [Cites] ANZ J Surg. 2003 Dec;73(12):988-95 [14632888.001]
  • (PMID = 18626704.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


9. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol; 2010 May 01;28(13):2159-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays.
  • This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Immunoassay. Mass Screening / methods. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Algorithms. CA-125 Antigen / blood. Carcinoembryonic Antigen / blood. Data Interpretation, Statistical. Early Detection of Cancer. Epididymal Secretory Proteins / analysis. Female. Humans. Middle Aged. Monte Carlo Method. Neoplasm Staging. Predictive Value of Tests. Prognosis. Reproducibility of Results. Sensitivity and Specificity. Vascular Cell Adhesion Molecule-1 / blood. beta-Defensins

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2010 May 1;28(13):2128-30 [20368556.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:418-34 [10800496.001]
  • [Cites] Life Sci. 2001 Jan 12;68(8):861-72 [11213356.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):643-50 [11237385.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Mol Pathol. 2002 Apr;55(2):110-20 [11950960.001]
  • [Cites] J Cancer Res Clin Oncol. 1989;115(5):456-8 [2808485.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):133-7 [10461006.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37 [10067810.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Gynecol Oncol. 1988 Jun;30(2):265-73 [3163666.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2837-44 [11753957.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4735-7 [9494598.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] Dis Markers. 2007;23(5-6):419-31 [18057525.001]
  • [Cites] JAMA. 1995 Dec 27;274(24):1926-30 [8568986.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2190-6 [10786683.001]
  • [Cites] Tumour Biol. 1993;14(2):105-15 [8392219.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4 [15904446.001]
  • [Cites] Curr Oncol Rep. 2002 Mar;4(2):165-74 [11822989.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):528-34 [15717649.001]
  • [Cites] Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4 [11176234.001]
  • [Cites] Cancer. 1975 May;35(5):1377-81 [47262.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):605-10 [12845660.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):131-40 [10411105.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4 [8297846.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):58-65 [17659325.001]
  • [Cites] J Surg Oncol. 1990 Jun;44(2):97-9 [2355747.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):464-75 [16083703.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2380-6 [11489816.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Mar;76(3):283-5 [9093148.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):61-79 [17275179.001]
  • [Cites] Semin Surg Oncol. 1994 Jul-Aug;10(4):242-8 [8091065.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Apr;99(4):329-32 [1581280.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1186-7 [7981074.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(3):265-312 [15307634.001]
  • [Cites] Clin Sci (Lond). 2006 Mar;110(3):279-91 [16464170.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Gynecol Oncol. 1988 Jan;29(1):66-75 [3422208.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3030-5 [10487660.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4059-66 [15381683.001]
  • [Cites] Medscape Womens Health. 1996 Nov;1(11):3 [9746655.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):23-35 [9511849.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):27-30 [9234916.001]
  • [Cites] Cytokine. 2009 Jan;45(1):44-9 [19058974.001]
  • [Cites] Biomed Biochim Acta. 1986;45(3):371-84 [3518711.001]
  • [Cites] Med Oncol. 2008;25(3):279-83 [18071928.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2743-6 [7532929.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Sep;104(9):1024-9 [9307529.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2891-4 [9713482.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):135-40 [10843471.001]
  • [Cites] Fertil Steril. 2003 Oct;80(4):1068-9; author reply 1069-70 [14556841.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Br J Obstet Gynaecol. 1979 Nov;86(11):901-4 [116672.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Hum Reprod. 2005 Jan;20(1):117-21 [15513972.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):185-92 [12218299.001]
  • [Cites] Cancer Invest. 1995;13(2):227-38 [7874576.001]
  • [Cites] Immunol Invest. 2006;35(2):167-79 [16698675.001]
  • [Cites] Eur Cytokine Netw. 2009 Mar;20(1):21-6 [19318317.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):248-52 [9648596.001]
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):379-84 [15645122.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 May 1;120(1):87-90 [15866092.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):201-7 [8031969.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1641-6 [16985025.001]
  • [Cites] Am Fam Physician. 2003 Sep 15;68(6):1075-82 [14524394.001]
  • (PMID = 20368574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / CA105009; United Kingdom / Medical Research Council / / G9901012; United States / NCI NIH HHS / CA / R01 CA108990; United Kingdom / Medical Research Council / / G0801228; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA086381
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Vascular Cell Adhesion Molecule-1; 0 / beta-Defensins
  • [Other-IDs] NLM/ PMC2860434
  •  go-up   go-down


10. Zhou X, Shang JQ, Zhou JN: [Transsacral local wide resection for mid-lower rectal tumors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan;12(1):44-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transsacral local wide resection for mid-lower rectal tumors].
  • OBJECTIVE: To evaluate the efficacy of transsacral local wide resection for mid-lower rectal tumors.
  • METHODS: Clinical data of 133 patients undergone transsacral local wide resection for mid-lower rectal tumors between September 1994 and September 2005 were analyzed retrospectively.
  • Postoperative diagnosis was adenoma in 28 patients, hyperplastic polyp in 3 patients, carcinoid in 8 patients, gastrointestinal stromal tumor in 1 patient,adenoma with intra-mucosal carcinogenesis in 29 patients and adenocarcinoma invading into submucosa in 64 patients.
  • CONCLUSION: Transsacral local wide resection is simple and safe for mid-lower rectal tumors, which is an appropriate procedure for mid-lower rectal benign tumor and can serve as a sphincter-saving operation for selected T(1) lower rectal carcinoma.
  • [MeSH-major] Rectal Neoplasms / surgery. Sacrococcygeal Region / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145503.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


11. Huang Z, Li L, Wang J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci; 2007 Sep;52(9):2287-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.
  • DNA methylation is a key mechanism of colorectal carcinogenesis.
  • Analysis of aberrantly methylation in stool DNA might provide a novel strategy for noninvasive detection of colorectal cancer (CRC).
  • To explore the feasibility of this approach, we have assessed the methylation status of secreted frizzled-related protein gene 2 (SFRP2) in stool samples from patients with CRC with respect to a series of healthy individuals and patients with benign colorectal diseases, using methylation-specific polymerase chain reaction.
  • Methylation testing of fecal DNA may be a simple, promising, and noninvasive screening tool for colorectal neoplasia.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colorectal Neoplasms. DNA Methylation. DNA, Neoplasm / analysis. Feces / chemistry. Membrane Proteins / genetics. Precancerous Conditions
  • [MeSH-minor] Apoptosis. Biopsy. Colonoscopy. Diagnosis, Differential. Disease Progression. Humans. Polymerase Chain Reaction. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Dis Sci. 2005 Nov;50(11):2147-52 [16240230.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):858-65 [11390535.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):142-9 [15704048.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1495-501 [15342451.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):29-39 [15000147.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Clin Chem. 2004 Nov;50(11):2179-82 [15502094.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Gut. 2004 Apr;53(4):573-80 [15016754.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1219-27 [11054379.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] Clin Colorectal Cancer. 2003 May;3(1):47-53 [12777192.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Nat Genet. 2002 Jun;31(2):141-9 [11992124.001]
  • (PMID = 17410438.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / SFRP2 protein, human
  •  go-up   go-down


12. De Chiara L, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Cordero OJ, Martínez-Ares D, Páez de la Cadena M: Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer; 2010;10:333
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas.
  • BACKGROUND: Serum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients compared to healthy donors, suggesting its potential utility for early diagnosis.
  • Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC.
  • RESULTS: At a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% (95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology.
  • CONCLUSIONS: Our preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening of CRC and advanced adenomas.
  • [MeSH-major] Adenoma / blood. Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Dipeptidyl Peptidase 4 / blood. Polyps / metabolism. Polyps / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Colonoscopy. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Sensitivity and Specificity. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Nov;83(9):1139-46 [11027426.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Feb 15;31(4):523-33 [19925498.001]
  • [Cites] N Engl J Med. 2001 Aug 23;345(8):555-60 [11529208.001]
  • [Cites] Scand J Immunol. 2001 Sep;54(3):249-64 [11555388.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1165-8 [11700264.001]
  • [Cites] Am J Gastroenterol. 2002 Dec;97(12):3186-94 [12492209.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):608-14 [12612899.001]
  • [Cites] Eur J Cell Biol. 2003 Feb;82(2):53-73 [12647932.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):259-69 [12785000.001]
  • [Cites] Dis Markers. 2003-2004;19(6):267-72 [15258327.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1996 Jan 18;334(3):155-9 [8531970.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1624-33 [16933324.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5600-5 [17575123.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70 [17895475.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1357-67 [18033685.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1349-54 [18316554.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):161-79 [18443206.001]
  • [Cites] World J Gastroenterol. 2008 May 7;14(17):2662-9 [18461651.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1541-9 [18479499.001]
  • [Cites] Int J Colorectal Dis. 2008 Apr;23(4):383-7 [18193432.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):275-81 [18979105.001]
  • [Cites] BMC Bioinformatics. 2009;10:209 [19586526.001]
  • [Cites] Dis Markers. 2009;27(6):311-6 [20075514.001]
  • [Cites] Oncology. 2000 Nov;59(4):310-6 [11096343.001]
  • (PMID = 20584285.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  • [Other-IDs] NLM/ PMC2912863
  •  go-up   go-down


13. Hardin RE, Ferzli GS, Zenilman ME, Gadangi PK, Bowne WB: Invasive amebiasis and ameboma formation presenting as a rectal mass: An uncommon case of malignant masquerade at a western medical center. World J Gastroenterol; 2007 Nov 14;13(42):5659-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 54-year-old man presented with rectal pain and bleeding secondary to ulcerated, necrotic rectal and cecal masses that resembled colorectal carcinoma upon colonoscopy.
  • These masses were later determined to be benign amebomas caused by invasive Entamoeba histolytica, which regressed completely with medical therapy.
  • In Western countries, the occurrence of invasive protozoan infection with formation of amebomas is very rare and can mistakenly masquerade as a neoplasm.
  • [MeSH-major] Entamoeba histolytica. Entamoebiasis / diagnosis. Rectal Diseases / diagnosis
  • [MeSH-minor] Animals. Colorectal Neoplasms / diagnosis. Diagnosis, Differential. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Amebiasis.
  • MedlinePlus Health Information. consumer health - Rectal Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17948943.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4172748
  •  go-up   go-down


14. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB: Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol; 2008 May 21;14(19):3074-80
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients.
  • AIM: To evaluate the diagnostic role of serum RASSF1A promoter hypermethylation in gastric and colorectal adenocarcinoma.
  • METHODS: Methylation-specific polymerase chain reaction (MSPCR) was used to examine the promoter methylation status of the serum RASSF1A gene in 47 gastric adenocarcinoma patients, 45 colorectal adenocarcinoma patients, 60 patients with benign gastrointestinal disease (30 with benign gastric disease and 30 with benign colorectal disease), and 30 healthy donor controls.
  • A paired study of RASSF1A promoter methylation status in primary tumor, adjacent normal tissue, and postoperative serum were conducted in 25 gastric and colorectal adenocarcinoma patients who later were underwent surgical therapy.
  • RESULTS: The frequencies of detection of serum RASSF1A promoter hypermethylation in gastric (34.0%) and colorectal (28.9%) adenocarcinoma patients were significantly higher than those in patients with benign gastric (3.3%) or colorectal (6.7%) disease or in healthy donors (0%) (P < 0.01).
  • The methylation status of RASSF1A promoter in serum samples was consistent with that in paired primary tumors, and the MSPCR results for RASSF1A promoter methylation status in paired preoperative samples were consistent with those in postoperative serum samples.
  • The serum RASSF1A promoter hypermethylation did not correlate with patient sex, age, tumor differentiation grade, surgical therapy, or serum carcinoembryonic antigen level.
  • CONCLUSION: Aberrant CpG island methylation within the promoter region of RASSF1A is a promising biomarker for gastric and colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Biomarkers, Tumor / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / blood. Promoter Regions, Genetic. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2000 Dec;30(3):211-4 [11147802.001]
  • [Cites] Oncol Rep. 2007 Nov;18(5):1225-30 [17914577.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):7034-8 [11585730.001]
  • [Cites] Mol Cell Biol. 2002 Jun;22(12):4309-18 [12024041.001]
  • [Cites] Oncogene. 2002 May 23;21(23):3792-5 [12032847.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1761-6 [12060614.001]
  • [Cites] Oncogene. 2002 Oct 17;21(47):7277-82 [12370819.001]
  • [Cites] Int J Cancer. 2002 Dec 20;102(6):623-8 [12448005.001]
  • [Cites] J Pathol. 2003 May;200(1):23-31 [12692837.001]
  • [Cites] Cancer Lett. 2003 Apr 25;193(2):207-16 [12706879.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):99-105 [12706863.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8125-36 [14603253.001]
  • [Cites] Int J Cancer. 2004 Aug 10;111(1):96-100 [15185349.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4244-50 [15205337.001]
  • [Cites] Cancer Res. 1977 Mar;37(3):646-50 [837366.001]
  • [Cites] Oncology. 1989;46(5):318-22 [2779946.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Semin Oncol. 1999 Oct;26(5):556-60 [10528904.001]
  • [Cites] World J Gastroenterol. 2004 Dec 1;10(23):3441-54 [15526363.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1219-25 [15709192.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1141-5 [15734995.001]
  • [Cites] Histol Histopathol. 2005 Apr;20(2):645-63 [15736067.001]
  • [Cites] Cancer Res. 2005 May 1;65(9):3682-90 [15867363.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):576-83 [15948711.001]
  • [Cites] Hepatogastroenterology. 2005 Jul-Aug;52(64):1293-6 [16001680.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5205-10 [16051962.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7653-9 [16140931.001]
  • [Cites] Oncogene. 2005 Nov 17;24(51):7630-4 [16007118.001]
  • [Cites] Lung Cancer. 2005 Dec;50(3):339-46 [16139926.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):315-9 [10888881.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):35669-72 [10998413.001]
  • [Cites] World J Gastroenterol. 2006 Jan 14;12(2):192-8 [16482617.001]
  • [Cites] J Biol Chem. 2006 Feb 24;281(8):4557-63 [16344548.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Lung Cancer. 2007 May;56(2):289-94 [17267069.001]
  • [Cites] BMC Cancer. 2007;7:120 [17608924.001]
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):242-51 [17652530.001]
  • [Cites] J Cell Sci. 2007 Sep 15;120(Pt 18):3163-72 [17878233.001]
  • [Cites] Mol Cell. 2007 Sep 21;27(6):962-75 [17889669.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):691-9 [11333291.001]
  • (PMID = 18494062.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC2712178
  •  go-up   go-down


15. Consolo P, Luigiano C, Pellicano R, Ferrara F, Giacobbe G, Morace C, Pallio S, Tortora A, Melita G, Bassi M, D'Imperio N, Alibrandi A, Familiari L: Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size. Minerva Med; 2010 Oct;101(5):311-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size.
  • AIM: The aim of this paper was to evaluate the outcome of endoscopic resection (ER) for pedunculated and non-pedunculated colorectal neoplasms exceeding 4 cm in size.
  • METHODS: All patients with a colorectal neoplasms measuring 4 cm or more, who underwent ER at our institution between January 1996 and December 2008 were included in the study.
  • The mean neoplasms size was 48.2±12.5 mm.
  • There were 32 sessile, 26 flat and 9 pedunculated neoplasms.
  • The most frequent type of neoplasm was villous adenoma (76.1%).
  • CONCLUSION: ER is a safe and effective procedure for removing benign appearing very large colorectal neoplasms.
  • [MeSH-major] Colonic Polyps / surgery. Colonoscopy. Colorectal Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Hemostasis, Surgical / methods. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / therapy. Tumor Burden

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Minerva Med. 2011 Apr;102(2):XV. Giuseppinella, M [corrected to Melita, G]
  • (PMID = 21048553.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


16. Smith A, Young GP, Cole SR, Bampton P: Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer; 2006 Nov 1;107(9):2152-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
  • The current study was conducted to undertake a paired comparison of a sensitive guaiac FOBT (GFOBT; Hemoccult II Sensa, Beckman Coulter, Fullerton, CA) with a brush-sampling FIT (InSure; Enterix, North Ryde, NSW, Australia), to determine whether this FIT improves detection of significant neoplasia.
  • Paired comparison of positivity rates was undertaken in those found to have cancer and/or significant adenoma (high-grade dysplasia, villous change, > or =10 mm, serrated histology or > or =3 polyps), benign pathology, or no pathology.
  • In analyses of just the screening cohort, the FIT remained significantly better at detecting cancers and significant adenomas; the false-positive rate for any neoplasia was marginally higher with the FIT than the GFOBT (3.4% vs. 2.5%; 95% CI of difference, 0-1.8%), whereas positive predictive values were 41.9% and 40.4%, respectively.
  • As such, it should deliver greater reductions in colorectal cancer mortality and incidence than the GFOBT.
  • [MeSH-major] Adenoma / diagnosis. Colorectal Neoplasms / diagnosis. Feces / chemistry. Guaiac. Hemoglobins / analysis. Occult Blood
  • [MeSH-minor] Aged. Australia / epidemiology. Cohort Studies. False Positive Reactions. Female. Humans. Immunochemistry. Indicators and Reagents. Male. Mass Screening / methods. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. GUM GUAIAC .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • [CommentIn] Cancer. 2007 May 1;109(9):1925-6; author reply 1926 [17370313.001]
  • (PMID = 16998938.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Indicators and Reagents; 9000-29-7 / Guaiac
  •  go-up   go-down


17. Choi YJ, Park SH, Lee SS, Choi EK, Yu CS, Kim HC, Kim JC: CT colonography for follow-up after surgery for colorectal cancer. AJR Am J Roentgenol; 2007 Aug;189(2):283-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT colonography for follow-up after surgery for colorectal cancer.
  • OBJECTIVE: The purpose of this article is to discuss the CT colonography (CTC) findings and the role of CTC for follow-up after curative surgery for colorectal cancer.
  • CONCLUSION: Contrast-enhanced CTC can be effective for surveillance for colorectal cancer recurrence after curative surgery because it enables simultaneous evaluation of distant abdominal metastasis, pericolic recurrence, intraluminal recurrence, and metachronous lesions.
  • The appearances of anastomotic recurrences at CTC overlap with those of more common inflammatory polyps and rare benign ulcers.
  • [MeSH-major] Colonography, Computed Tomographic / methods. Colorectal Neoplasms / radiography. Colorectal Neoplasms / surgery
  • [MeSH-minor] Colonic Polyps / radiography. Colonoscopy. Contrast Media. Humans. Neoplasm Recurrence, Local / radiography. Postoperative Complications / radiography. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646452.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 13
  •  go-up   go-down


18. Metser U, You J, McSweeney S, Freeman M, Hendler A: Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen. AJR Am J Roentgenol; 2010 Mar;194(3):766-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
  • OBJECTIVE: The purpose of this study was to compare FDG PET/CT and contrast-enhanced 64-MDCT of the chest, abdomen, and pelvis in the detection of tumor recurrence in patients with colorectal cancer and an elevated level of carcinoembryonic antigen (CEA).
  • MATERIALS AND METHODS: A retrospective analysis included 50 patients (31 men, 19 women; mean age, 61 years; range, 28-89 years) with 55 clinical events of elevated or increasing CEA level who underwent FDG PET/CT and MDCT for suspected tumor recurrence.
  • Fifty-four of 61 tumor sites suspected as tumor recurrence with any imaging technique were found to be local recurrence or metastatic colorectal cancer at final analysis.
  • The other seven sites were one separate malignant tumor (small lymphocytic lymphoma) and six benign lesions.
  • Diagnosis was based on histopathologic findings (n = 27) or clinical and imaging findings (n = 35) during a median follow-up period of 12 months (range, 6-31 months).
  • One site of tumor recurrence was missed prospectively at both MDCT and PET/CT.
  • In a tumor site-based analysis, the sensitivities of PET/CT and MDCT were 98.1% and 66.7% (p < 0.0001), and the specificities were 75% and 62.5% (p = 0.56).
  • Tumors correctly identified with PET/CT and missed with MDCT were local recurrence in the presacral space (n = 5), metastatic subcentimeter lymph nodes (n = 4), peritoneal deposits (n = 3), and recurrences at the periphery of radiofrequency ablated metastatic lesions of the liver (n = 2) and in the abdominal wall (n = 1), liver (n = 1), and uterine cervix (n = 1).
  • CONCLUSION: FDG PET/CT has higher sensitivity than MDCT in the identification of sites of recurrent and metastatic disease in patients with colorectal cancer and an elevated CEA level.
  • [MeSH-major] Colorectal Neoplasms / radiography. Colorectal Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoembryonic Antigen / blood. Contrast Media. Female. Humans. Male. Middle Aged. Neoplasm Metastasis / radiography. Neoplasm Metastasis / radionuclide imaging. Radiographic Image Interpretation, Computer-Assisted. Radiography, Abdominal. Radiography, Thoracic. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173157.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Contrast Media; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


19. Kume K, Murata I, Yoshikawa I, Yamasaki M, Kanda K, Otsuki M: Endoscopic piecemeal mucosal resection of large colorectal tumors. Hepatogastroenterology; 2005 Mar-Apr;52(62):429-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic piecemeal mucosal resection of large colorectal tumors.
  • BACKGROUND/AIMS: Since endoscopic en bloc resection of large and sessile tumors is technically difficult, endoscopic en bloc piecemeal mucosal resection (EPMR) is usually chosen for resection of such tumors.
  • Tumors resected by EPMR are, however, difficult to evaluate histologically.
  • METHODOLOGY: We removed 30 large colorectal tumors in 30 patients by EPMR between 1992-2000.
  • Patients in whom no residual tumor was found by both endoscopic and histologic examination were considered to be "cured".
  • RESULTS: Histological examination of the resected tumor tissues revealed malignancy in 43.3% (13/30).
  • Three patients had invasive malignant tumors and underwent surgery.
  • Following complete endoscopic resection, recurrences were observed in 2 patients with benign tumors, which were resected by additional endoscopic resection.
  • All patients including the two with non-invasive malignant tumors remain free from recurrence during a mean follow-up period of 45.2 months (range, 3-104 months).
  • CONCLUSIONS: EPMR of benign or non-invasive large malignant tumors is a safe and effective procedure.
  • Complete excision of large, sessile and non-invasive tumors is possible, although complete removal by EPMR cannot be verified histologically.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Digestive System / methods. Intestinal Mucosa / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816450.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


20. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol; 2005 Dec;18(12):1591-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Then, we evaluated the feasibility of GPC3-immunohistochemistry in the pathological diagnosis of benign and malignant hepatocellular lesions by applying these monoclonal antibodies to formalin-fixed and paraffin-embedded specimens.
  • GPC3 immunoreactivity was detected in only one of 23 metastatic lesions of colorectal carcinoma, and its expression was entirely absent in the liver cell adenoma (0/7), carcinoid tumor (0/1), and cholangiocellular carcinoma (0/16).
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / diagnosis. Heparan Sulfate Proteoglycans / metabolism. Liver Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / biosynthesis. Antibodies, Monoclonal / immunology. Cell Line, Tumor. Glypicans. Hepatoblastoma / metabolism. Hepatoblastoma / pathology. Hepatocytes / metabolism. Hepatocytes / pathology. Humans. Liver / embryology. Liver / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920546.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Heparan Sulfate Proteoglycans
  •  go-up   go-down


21. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, Murayama S, Mori M: Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res; 2005 Apr 15;11(8):2889-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer.
  • The purpose of the current study was to quantify the expression of KLK6 in malignant and benign colorectal tissues and to statistically analyze whether KLK6 expression levels correlate with clinicopathologic variables and prognosis in patients with colorectal cancer.
  • EXPERIMENTAL DESIGNS: Paired colorectal tissue samples from cancerous and corresponding noncancerous tissues were obtained from 63 patients with colorectal cancer who underwent surgical resection.
  • CONCLUSIONS: The results of this study indicated that KLK6 mRNA expression was significantly higher in cancerous than in noncancerous colorectal tissues, and high expression of KLK6 mRNA correlated with serosal invasion, liver metastasis, advanced Duke's stage, and a poor prognosis for patients with colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Kallikreins / genetics. RNA, Messenger / metabolism
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837738.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


22. Jiang W, Fujii H, Matsumoto T, Ohtsuji N, Tsurumaru M, Hino O: Birt-Hogg-Dubé (BHD) gene mutations in human gastric cancer with high frequency microsatellite instability. Cancer Lett; 2007 Apr 8;248(1):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé (BHD) syndrome is a rare inherited genodermatosis characterized by benign hamartomatous skin lesions and an increased risk of pneumothorax and renal tumors.
  • This mutational hot spot is also reported to be a target of mutation in microsatellite instability (MSI) sporadic colorectal tumors.
  • [MeSH-major] Microsatellite Instability. Mutation. Proteins / genetics. Proto-Oncogene Proteins / genetics. Stomach Neoplasms / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Exons / genetics. Female. Gene Frequency. Humans. Male. Middle Aged. Neoplasm Staging. Poly C / genetics. Protein-Serine-Threonine Kinases. Receptors, Transforming Growth Factor beta / genetics. bcl-2-Associated X Protein / genetics

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16870330.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / FLCN protein, human; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 30811-80-4 / Poly C; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


23. Frühmorgen P: [Prevention and early detection of colorectal cancer]. Praxis (Bern 1994); 2005 Oct 26;94(43):1687-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevention and early detection of colorectal cancer].
  • With 60000 new cases and approximately 31000 deaths annually the colorectal carcinoma is the second most frequent cause of death due to a tumour in Germany.
  • In over 90% of all colorectal carcinomas the precursors (adenomas) are well known.
  • Moreover the early carcinoma of the colorectum (pT1-carcinoma) has an exceptional benign prognosis.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / prevention & control. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / prevention & control
  • [MeSH-minor] Adenoma / diagnosis. Adenoma / surgery. Colonic Polyps / diagnosis. Colonic Polyps / surgery. Colonoscopy. Early Diagnosis. Humans. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / prevention & control. Neoplasm Staging. Precancerous Conditions / diagnosis. Precancerous Conditions / mortality. Precancerous Conditions / pathology. Precancerous Conditions / prevention & control. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16276764.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


24. Amato A: Colorectal gastrointestinal stromal tumor. Tech Coloproctol; 2010 Nov;14 Suppl 1:S91-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal gastrointestinal stromal tumor.
  • Gastrointestinal stromal tumor (GIST) is the most common mesenchymal neoplasm arising in the digestive tract, with an estimated prevalence of 15-20 per 1,000,000.
  • Colorectal GISTs represent about 5-10% of the cases, mainly located in the rectum that is the third common site.
  • Benign GISTs are more common, but many tumors are of uncertain malignant potential; tumor size and rate of mitosis are still the most reliable criteria for assessing the risk of an aggressive behavior.
  • Surgery is the first-line treatment for resectable non-metastatic colorectal GIST.
  • Segmental colectomy with negative margins is recommended, and local excision is oncologically adequate in highly selected rectal tumors.
  • [MeSH-major] Colorectal Neoplasms. Gastrointestinal Stromal Tumors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2000 Jan;231(1):51-8 [10636102.001]
  • [Cites] Br J Surg. 2003 Oct;90(10):1178-86 [14515284.001]
  • [Cites] Ann Surg Oncol. 2000 Oct;7(9):705-12 [11034250.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S37-8 [12528771.001]
  • [Cites] Arch Surg. 2001 Apr;136(4):383-9 [11296107.001]
  • [Cites] Am J Surg Pathol. 1983 Sep;7(6):507-19 [6625048.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):89-96 [17145623.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14):2006-11 [12957454.001]
  • [Cites] Int J Colorectal Dis. 2007 Aug;22(8):981-2 [16583196.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1052-6 [11287975.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1098-103 [15522557.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] Hum Pathol. 2002 May;33(5):459-65 [12094370.001]
  • [Cites] Lancet. 2004 Sep 25-Oct 1;364(9440):1127-34 [15451219.001]
  • [Cites] Dis Colon Rectum. 2006 May;49(5):609-15 [16552495.001]
  • [Cites] Ann Surg Oncol. 2007 Jan;14(1):14-24 [17072676.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S60-5 [12528774.001]
  • [Cites] J Clin Oncol. 2003 Dec 1;21(23):4342-9 [14645423.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1259-69 [9588894.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):526-32 [17139461.001]
  • [Cites] Science. 1998 Jan 23;279(5350):577-80 [9438854.001]
  • [Cites] Dis Colon Rectum. 2005 Jun;48(6):1316-9 [15793646.001]
  • [Cites] J Surg Oncol. 2009 Jan 1;99(1):42-7 [18942073.001]
  • [Cites] Int J Colorectal Dis. 2007 Feb;22(2):109-14 [16639561.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1121-33 [11688571.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1091-5 [11021812.001]
  • [Cites] Am J Surg Pathol. 2003 May;27(5):625-41 [12717247.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Feb;18(2):147-51 [12542597.001]
  • [Cites] Am J Surg. 2006 Jan;191(1):121-3 [16399120.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2325-31 [16710031.001]
  • [Cites] Am J Surg Pathol. 1999 Aug;23(8):937-45 [10435564.001]
  • [Cites] Gastroenterol Clin Biol. 2007 Jun-Jul;31(6-7):585-93 [17646785.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):162-8 [15654796.001]
  • [Cites] Mod Pathol. 1998 Aug;11(8):728-34 [9720500.001]
  • [Cites] Dis Colon Rectum. 2004 Nov;47(11):1922-9 [15622586.001]
  • [Cites] Pol J Pathol. 2003;54(1):3-24 [12817876.001]
  • [Cites] Clin Cancer Res. 2004 May 15;10(10):3282-90 [15161681.001]
  • [Cites] Surg Today. 2007;37(6):455-9 [17522761.001]
  • [Cites] Surg Today. 2007;37(8):698-701 [17643218.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):66-74 [10618607.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):791-5 [10702394.001]
  • [Cites] Cancer. 2005 Feb 15;103(4):821-9 [15648083.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1134-42 [11048809.001]
  • [Cites] Br J Surg. 2003 Mar;90(3):332-9 [12594669.001]
  • [Cites] Eur J Cancer. 2003 Sep;39(14 ):2012-20 [12957455.001]
  • [Cites] Am J Surg Pathol. 2004 Jul;28(7):889-94 [15223958.001]
  • [Cites] Ann Chir Gynaecol. 1998;87(4):278-81 [9891765.001]
  • [Cites] Cancer Res. 2001 Nov 15;61(22):8118-21 [11719439.001]
  • [Cites] Am J Surg Pathol. 2000 Jul;24(7):947-57 [10895817.001]
  • [Cites] Am J Pathol. 1999 Jan;154(1):53-60 [9916918.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1692-703 [11896121.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):660-7 [12949711.001]
  • [Cites] Scand J Surg. 2003;92(3):195-9 [14582540.001]
  • [Cites] Am J Surg Pathol. 2000 Oct;24(10):1339-52 [11023095.001]
  • [Cites] Colorectal Dis. 2008 Nov;10 (9):951-2 [18294266.001]
  • [Cites] Eur J Cancer. 2002 Sep;38 Suppl 5:S83-7 [12528778.001]
  • (PMID = 20967481.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


25. Amosenko FA, Korchagina EL, Matveeva TI, Vaganov IuE, Vlasov SB, Poltavets NV, Veselov VV, Gar'kavtseva RF, Poliakov AV: [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients]. Genetika; 2010 May;46(5):700-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients].
  • To estimate diagnostic value of K-ras mutations during cancer risk group formation, they were studied in the samples of sporadic carcinomas (n = 33) and malignant (n = 13) polyps of large intestine obtained during surgery or polypectomy.
  • Mutation frequency in carcinomas, benign and malignant polyps was 43, 49, and 69%, respectively.
  • In the healthy tissue of the large intestine, no changes in codons 12 and 13 in the K-ras gene were observed.
  • In patients with colorectal carcinoma the mutation frequency in the K-ras gene was not associated with disease onset age, location, and the extent of tumor differentiation while it was associated with the stage of tumor process.
  • The maximum mutation frequency was revealed in polyps of patients over 70 years of age as well as in the adenomas of villous histology and large size ((1 cm).
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA, Neoplasm / genetics. Genes, ras / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583607.001).
  • [ISSN] 0016-6758
  • [Journal-full-title] Genetika
  • [ISO-abbreviation] Genetika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  •  go-up   go-down


26. Terzi C, Unek T, Sağol O, Yilmaz T, Füzün M, Sökmen S, Ergör G, Küpelioğlu A: Is rectal washout necessary in anterior resection for rectal cancer? A prospective clinical study. World J Surg; 2006 Feb;30(2):233-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Implantation of exfoliated malignant cells has been suggested as a possible mechanism of tumor recurrence in colorectal anastomoses that might be prevented by cytocidal washout.
  • The fluid was then classified as "acellular," "malignant cells identified," or "benign cells identified" by pathologists.
  • There is a need for a randomized, controlled, large-scale, multicenter trial to establish the clinical relevance of intraoperative rectal washout.
  • [MeSH-major] Colectomy / methods. Neoplasm Recurrence, Local / prevention & control. Neoplasm Seeding. Peritoneal Lavage / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Aged. Anastomosis, Surgical. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Male. Middle Aged. Neoplasm Staging. Probability. Prospective Studies. Reference Values. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Dec 1;52(11):1986-92 [6354419.001]
  • [Cites] Aust N Z J Surg. 1965 Feb;34:178-87 [14271060.001]
  • [Cites] Ann R Coll Surg Engl. 1979 Jul;61(4):251-7 [382965.001]
  • [Cites] Br J Surg. 1985 Aug;72(8):602 [4027530.001]
  • [Cites] Br J Surg. 1995 Aug;82(8):1050-2 [7648150.001]
  • [Cites] Ann R Coll Surg Engl. 1989 Jan;71(1):54-6 [2923422.001]
  • [Cites] Dis Colon Rectum. 2005 Mar;48(3):411-23 [15875292.001]
  • [Cites] Br J Surg. 1987 Nov;74(11):1049-52 [3690235.001]
  • [Cites] Ann Surg. 1998 Jun;227(6):800-11 [9637543.001]
  • [Cites] Lancet. 1986 Jun 28;1(8496):1479-82 [2425199.001]
  • [Cites] Surg Gynecol Obstet. 1988 Apr;166(4):357 [3353834.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):659-63 [6478151.001]
  • [Cites] Dis Colon Rectum. 2000 Dec;43(12):1710-2 [11156455.001]
  • [Cites] Dis Colon Rectum. 1985 Mar;28(3):164-7 [3971822.001]
  • [Cites] Acta Chir Belg. 1994 Sep-Oct;94(5):258-62 [7976066.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):389-402 [12626917.001]
  • [Cites] Br J Surg. 1984 Sep;71(9):664-5 [6478153.001]
  • [Cites] Br J Surg. 2002 Feb;89(2):206-7 [11856135.001]
  • [Cites] Dis Colon Rectum. 1985 Apr;28(4):260-1 [3979229.001]
  • [Cites] Dis Colon Rectum. 1992 Mar;35(3):238-41 [1740068.001]
  • [Cites] Br J Surg. 1989 Apr;76(4):331-4 [2541860.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):291-6 [14991490.001]
  • [Cites] Dis Colon Rectum. 1998 Sep;41(9):1127-33 [9749496.001]
  • [Cites] Surg Today. 1997;27(5):457-9 [9130352.001]
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):583-96 [11309435.001]
  • [Cites] Ann Med. 1997 Apr;29(2):91-3 [9187224.001]
  • [Cites] Dis Colon Rectum. 1998 Nov;41(11):1432-4 [9823812.001]
  • [Cites] Br J Surg. 1984 Feb;71(2):98-100 [6692125.001]
  • [Cites] Br J Surg. 1982 May;69(5):275-6 [7074339.001]
  • [Cites] Lancet. 1986 Nov 1;2(8514):996-9 [2430152.001]
  • (PMID = 16425079.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Whitehouse PA, Armitage JN, Tilney HS, Simson JN: Transanal endoscopic microsurgery: local recurrence rate following resection of rectal cancer. Colorectal Dis; 2008 Feb;10(2):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Transanal endoscopic microsurgery (TEM) is a safe and effective treatment for the excision of benign rectal adenomas.
  • [MeSH-major] Endoscopy, Digestive System / methods. Microsurgery / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Chi-Square Distribution. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Staging. Palliative Care. Prospective Studies. Statistics, Nonparametric. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17608750.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Brent A, Talbot R, Coyne J, Nash G: Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer? Colorectal Dis; 2007 Nov;9(9):816-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer?
  • OBJECTIVE: The aim of this study was to determine the significance of indeterminate lung lesions reported from staging CT scans on patients with colorectal cancer.
  • The tumour, node, metastasis (TNM) stage of these patients was recorded together with any follow-up scan reports or multidisciplinary team (MDT) discussions regarding these lesions.
  • In 19, the indeterminate lesions were unchanged and were therefore downgraded to benign lesions.
  • Indeterminate lung lesions are not a reason to delay surgery for colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Lung / pathology. Lung / radiography. Lung Neoplasms / secondary
  • [MeSH-minor] Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Neoplasm Staging. Tomography, Spiral Computed


29. Radulescu S, Ridgway RA, Appleton P, Kroboth K, Patel S, Woodgett J, Taylor S, Nathke IS, Sansom OJ: Defining the role of APC in the mitotic spindle checkpoint in vivo: APC-deficient cells are resistant to Taxol. Oncogene; 2010 Dec 09;29(49):6418-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Mutations in the adenomatous polyposis coli (APC) tumour suppressor are the key initiating event of colorectal cancer.
  • Although the control of WNT signalling is well established as a central tumour-suppressive function, the significance of APC in regulating chromosome instability is less well established.
  • Importantly, this dose of Taxol strongly suppresses intestinal tumourigenesis in models of benign (APC(Min/+) mouse) and invasive (AhCreER(+)APC(fl/+)PTEN(fl/fl)) cancer.
  • [MeSH-major] Adenomatous Polyposis Coli / drug therapy. Adenomatous Polyposis Coli Protein / physiology. Antineoplastic Agents, Phytogenic / therapeutic use. Drug Resistance, Neoplasm / genetics. Paclitaxel / therapeutic use. Spindle Apparatus / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 2005 Aug;129(2):626-38 [16083717.001]
  • [Cites] Mol Biol Cell. 2005 Oct;16(10):4609-22 [16030254.001]
  • [Cites] EMBO J. 2006 Jun 21;25(12):2814-27 [16763565.001]
  • [Cites] J Cell Biol. 2007 Jan 15;176(2):183-95 [17227893.001]
  • [Cites] Mol Biol Cell. 2007 Mar;18(3):910-8 [17192415.001]
  • [Cites] Nature. 2007 Apr 5;446(7136):676-9 [17377531.001]
  • [Cites] J Cell Biol. 2007 Sep 24;178(7):1109-20 [17893240.001]
  • [Cites] Dev Cell. 2007 Oct;13(4):566-79 [17925231.001]
  • [Cites] J Cell Biol. 2008 Jun 2;181(5):719-26 [18519734.001]
  • [Cites] Cancer Cell. 2008 Aug 12;14(2):111-22 [18656424.001]
  • [Cites] Mol Cell Biol. 2008 Oct;28(20):6314-28 [18694957.001]
  • [Cites] Nat Genet. 2008 Dec;40(12):1436-44 [19011632.001]
  • [Cites] Cell Motil Cytoskeleton. 2001 May;49(1):1-15 [11309836.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):429-32 [11283619.001]
  • [Cites] Cancer Cell. 2009 Oct 6;16(4):347-58 [19800579.001]
  • [Cites] Nat Cell Biol. 2001 Apr;3(4):433-8 [11283620.001]
  • [Cites] Trends Cell Biol. 2001 Sep;11(9):378-84 [11514192.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):674-81 [12566313.001]
  • [Cites] Gastroenterology. 2004 May;126(5):1236-46 [15131783.001]
  • [Cites] Mol Biol Cell. 2004 Jun;15(6):2978-91 [15075372.001]
  • [Cites] J Cell Biol. 2004 Jun 7;165(5):609-15 [15184397.001]
  • [Cites] Genes Dev. 2004 Jun 15;18(12):1385-90 [15198980.001]
  • [Cites] Nucleic Acids Res. 2004;32(11):e92 [15247325.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Onkologie. 1991 Feb;14(1):7-12 [2057177.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2972-7 [7606712.001]
  • [Cites] Eur J Cancer. 1995 Jul-Aug;31A(7-8):1291-4 [7577038.001]
  • [Cites] Science. 1997 Oct 3;278(5335):120-3 [9311916.001]
  • [Cites] Curr Biol. 1998 Oct 22;8(21):1169-78 [9799734.001]
  • [Cites] Cell. 1999 Jan 8;96(1):79-88 [9989499.001]
  • [Cites] J Cell Sci. 2004 Dec 15;117(Pt 26):6339-53 [15561772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 17;102(20):7286-91 [15857952.001]
  • (PMID = 20729907.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A11243; Canada / Canadian Institutes of Health Research / / 12858; United Kingdom / Cancer Research UK / / 11243; United Kingdom / Cancer Research UK / / ; Canada / Canadian Institutes of Health Research / / 74711; United Kingdom / Cancer Research UK / / A7130; United Kingdom / Cancer Research UK / / 11913
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Antineoplastic Agents, Phytogenic; 0 / Wnt Proteins; 5V9KLZ54CY / Vinblastine; EC 2.7.11.1 / Bub1 protein, mouse; EC 2.7.11.1 / Bub1 spindle checkpoint protein; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; P88XT4IS4D / Paclitaxel; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC3016607; NLM/ UKMS31064
  •  go-up   go-down


30. Wichmann MW, Hüttl TP, Winter H, Spelsberg F, Angele MK, Heiss MM, Jauch KW: Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg; 2005 Jul;140(7):692-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study.
  • HYPOTHESIS: Laparoscopy has become a popular approach for the surgical treatment of benign and even malignant colorectal diseases.
  • Several authors have reported better preserved immunity in patients undergoing laparoscopic compared with conventional colorectal surgery.
  • The present study addresses the hypothesis that specific and nonspecific immunity are differently affected by laparoscopic and conventional colorectal surgery.
  • PATIENTS: Seventy prospectively enrolled patients with colorectal diseases undergoing laparoscopic (n = 35) or open (n = 35) surgery.
  • The levels of B lymphocytes and T lymphocytes and helper T-cell counts and cytotoxic (suppressor) T-cell counts did not show significant differences after open or laparoscopic surgery.
  • These findings are important because a divergent effect on specific and nonspecific immunity of laparoscopic surgery for colorectal disease has not been reported before.
  • [MeSH-major] Colorectal Neoplasms / immunology. Colorectal Neoplasms / surgery. Immunity, Cellular / physiology. Laparoscopy / methods. Laparotomy / methods. Postoperative Complications / immunology
  • [MeSH-minor] Aged. Analysis of Variance. Biomarkers / blood. Female. Hospitals, University. Humans. Immunocompetence / physiology. Inflammation Mediators / analysis. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027336.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Inflammation Mediators
  •  go-up   go-down


31. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • AIM: To analyze vascular endothelial growth factor (VEGF), c-erbB-2 and c-erbB-3 expression and to evaluate their relation to clinicopathologic parameters and pathogenesis of colorectal carcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


32. Zammit M, Jenkins JT, Urie A, O'Dwyer PJ, Molloy RG: A technically difficult endorectal ultrasound is more likely to be inaccurate. Colorectal Dis; 2005 Sep;7(5):486-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific reasons for inaccuracy identified in this group were: inflammatory lymph nodes (from a tumour associated abscess and a colovesical fistula) and deep biopsy causing a submucosal defect with intramural haemorrhage in benign lesions (2 cases).
  • In the remaining 39 (33.3%), the following problems were encountered: stenotic lesions (23), patient discomfort (8), poor bowel preparation (6), and scarring from previous surgery (2).
  • [MeSH-major] Endosonography / methods. Rectal Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Aged, 80 and over. Chi-Square Distribution. Diagnostic Errors. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108886.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


33. Wang S, Bromley E, Xu L, Chen JC, Keltner L: Talaporfin sodium. Expert Opin Pharmacother; 2010 Jan;11(1):133-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic antitumor effects mediated by CD8(+) T cells have been demonstrated in preclinical studies, providing a mechanism for distant response of tumors noted in clinical trials.
  • Phase I and II studies in solid tumors have shown tumor regression in patients refractory to other therapies.
  • Phase III pivotal studies against hepatocellular carcinoma as monotherapy and liver-metastatic colorectal cancer in combination with chemotherapy are ongoing.
  • Talaporfin sodium is also in studies in men with symptomatic benign prostatic hyperplasia.
  • WHAT THE READER WILL GAIN: Talaporfin sodium has a broad safety profile and a mode of action that could affect growth in treated and untreated tumors.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Porphyrins / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cancer Vaccines / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Clinical Trials, Phase III as Topic. Combined Modality Therapy / methods. Humans. Japan / epidemiology. Male. Neoplasm Staging. Neoplasms. Oxides / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001435.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines; 0 / Oxides; 0 / Porphyrins; P4ROX5ELT2 / Talaporfin
  • [Number-of-references] 29
  •  go-up   go-down


34. Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA: WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res; 2008 Mar 1;14(5):1397-406
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prostate cancer is the third leading cause of cancer death in the United States, following lung and colorectal cancer.
  • Here, we evaluate its utility as a prostate cancer tissue marker for diagnosis and prognostic evaluation.
  • After generating antibodies against WDR19, tissue microarrays (TMA) were employed to compare WDR19 expression between normal, benign prostatic hyperplasia, and prostate cancer tissue.
  • Large-scale immunohistochemical staining using TMAs reveals a significant percentage of increase in intensely staining tissue cores in cancer tissue when compared with normal or benign prostatic hyperplastic tissue.
  • The continued expansion of a multiple-marker panel will conceivably increase the sensitivity and specificity of prostate cancer diagnosis and prognosis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316561.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P50 GM076547; United States / NIGMS NIH HHS / GM / 5P50GM076547; United States / NCI NIH HHS / CA / 5U54CA119347
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Proteins; 0 / RNA, Messenger; 0 / WDR19 protein, human; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


35. Pillinger SH, Monson JR: Laparoscopy for colorectal malignancy. Dig Surg; 2005;22(1-2):34-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy for colorectal malignancy.
  • Laparoscopy for colorectal pathology is technically demanding with a steep learning curve.
  • In expert hands, there is no doubt that there is a place for laparoscopy in the operative armamentarium for the treatment of benign disease.
  • The evidence available suggests that laparoscopic resection is a feasible and appropriate option for the treatment of colorectal carcinoma.
  • [MeSH-major] Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Anastomosis, Surgical. Clinical Competence. Humans. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838169.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 82
  •  go-up   go-down


36. Croce MV, Isla-Larrain M, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A: MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol; 2006 08;21(8):849-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue.
  • MATERIALS AND METHODS: We studied 163 breast and 89 colorectal cancer specimens, 10 breast and 14 colorectal benign conditions, and 12 breast and 20 colorectal normal samples.
  • From each tumor sample, subcellular fractions were obtained and analyzed by SDS-PAGE and WB.
  • Seven out of ten (70%) benign breast specimens were positive with CT33 while all samples stained with CT2; in normal breast sample tissues, all were positive with both Abs.
  • In colorectal cancer samples, both antibodies stained 47/89 (53%) samples; CT2 reacted in 13/14 (93%) of benign samples while CT33 showed a positive reaction in 9/14 (64%) of benign specimens.
  • By WB, in breast and colorectal cancer samples, similar results were obtained with both antibodies: a main band at about 30kDa which represents the smaller subunit.
  • CONCLUSION: CT33 polyclonal antibody has demonstrated its efficacy to detect MUC1 in breast and colorectal cancer tissues with similar reactivity to CT2.
  • [MeSH-major] Antibodies, Monoclonal / metabolism. Breast Neoplasms / metabolism. Colorectal Neoplasms / metabolism. Mucin-1 / metabolism. Organic Cation Transport Proteins / metabolism
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antibodies, Neoplasm / metabolism. Biomarkers, Tumor. Breast / anatomy & histology. Breast / metabolism. Breast / pathology. Cell Fractionation. Colon / anatomy & histology. Colon / metabolism. Colon / pathology. Humans. Immunoenzyme Techniques. Rectum / anatomy & histology. Rectum / metabolism. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691537.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC-1 monoclonal antibody; 0 / Mucin-1; 0 / Organic Cation Transport Proteins; 0 / SLC22A16 protein, human
  •  go-up   go-down


37. Yu YJ, Liu YD, Xu X, Ma XW: [Diagnostic significance of cytokeratin 19 and 20 expression on micrometastasis of colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan;12(1):48-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic significance of cytokeratin 19 and 20 expression on micrometastasis of colorectal cancer].
  • OBJECTIVE: To inquire into the diagnostic significance of cytokeratin 19(CK19) and cytokeratin 20(CK20) expression on hematogenous micrometastasis of colorectal cancer.
  • METHODS: Forty-four patients with colorectal cancer were collected as colorectal cancer groups, and another 18 patients treated with abdominal surgical operations because of benign diseases were collected as benign disease group.
  • RESULTS: There were no positive expression of CK19 and CK20 in the portal and peripheral blood of all the patients in benign disease group.
  • Of the colorectal cancer group, 34 patients(77.3%) appeared positive expressions of CK19 and/or CK20 in portal and peripheral blood, and there was significant difference in the expressions of CK19 and CK20 between the two groups(P<0.05).
  • Within the colorectal cancer group, the positive expression rates of CK19 and CK20 in peripheral blood were 36.4% and 52.3%, and the rates in portal blood were 59.1% and 72.7%.
  • The postoperative metastasis and recurrence rate of colorectal cancer in patients with positive expression of CK19 and CK20 in peripheral blood was 61.5%, which was significantly higher than that(25.0%) in patients with positive expression in portal blood only(P<0.05).
  • CONCLUSIONS: In patients with colorectal cancer, the expressions of CK19 and CK20, which are determined by RT-PCR in blood from portal and peripheral veins, are the sensitive and specific indexes for diagnosing hematogenous micrometastasis of the cancer.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Keratin-19 / blood. Keratin-20 / blood
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145504.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / Keratin-20
  •  go-up   go-down


38. Togashi K, Shimura K, Konishi F, Miyakura Y, Koinuma K, Horie H, Yasuda Y: Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy. Dis Colon Rectum; 2008 Feb;51(2):196-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy.
  • PURPOSE: This study was designed to confirm the safety of not removing small adenoma in patients who undergo colorectal cancer surgery.
  • Benign adenomas of 6 mm or less in size, diagnosed based on both nonmagnified and magnified observation, were left unresected with a maximum of three polyps per patient.
  • CONCLUSIONS: Leaving small polyps is safe even in patients who have undergone colorectal cancer surgery, provided that careful observation is guaranteed.
  • [MeSH-major] Adenoma / diagnosis. Colonic Polyps / surgery. Colonoscopy / methods. Digestive System Surgical Procedures / methods. Neoplasms, Second Primary / diagnosis. Postoperative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Reoperation


39. Hedrick TL, Galloway RP, McElearney ST, Smith RL, Ledesma EJ, Wilson WH, Sawyer RG, Friel CM, Foley EF: Screening practices of patients presenting for resection of a colorectal neoplasm. Am Surg; 2006 Jan;72(1):89-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening practices of patients presenting for resection of a colorectal neoplasm.
  • Multiple studies demonstrate the efficacy of colorectal cancer (CRC) screening in patients over 50 years of age.
  • The objective of this study was to identify the CRC screening practices at two institutions and determine the relationship between screening and pathologic stage for patients presenting with a colorectal neoplasm.
  • This study, conducted at the University of Virginia (UVA) Health System and the Salem Veterans Affairs Medical Center (VAMC) between October 30, 2000, and September 1, 2004, included 198 patients > or = 50 years who presented for resection of a primary colorectal neoplasm.
  • Ninety-one per cent of patients with benign polyps had been screened prior to diagnosis, compared with 72 per cent of patients with stage I and II cancer and 54 per cent of patients with stage III and IV cancer (P < 0.05).
  • CRC screening facilitates diagnosis at an early stage.
  • [MeSH-major] Colectomy. Colorectal Neoplasms. Mass Screening / methods
  • [MeSH-minor] Aged. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494194.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


40. Olgac S, Hutchinson B, Tickoo SK, Reuter VE: Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma. Mod Pathol; 2006 Feb;19(2):218-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
  • Metanephric adenoma (MA), a well-described renal neoplasm, usually behaves in a benign fashion.
  • It may have areas that are morphologically similar to papillary renal cell carcinoma (RCC) type, or epithelial (tubular predominant) type Wilms' tumor.
  • Alpha-methylacyl-CoA racemase (AMACR), a molecular marker for prostate carcinoma, has subsequently been found to be overexpressed in breast, colorectal and ovarian cancers, among others.
  • Recent microarray analysis of renal tumors has shown an increase of AMACR mRNA levels in papillary RCC but not in other subtypes.
  • We investigated the utility of immunohistochemical staining for AMACR, cytokeratin 7(CK7), CD57 and WT1 to differentiate between the above-mentioned three neoplasms.
  • Immunohistochemical stains were performed on paraffin-embedded tissue sections from 25 papillary RCC, 10 MAs and eight Wilms' tumors.
  • AMACR was positive in one (10%) of 10 MAs and 24 (96%) of 25 papillary RCC, while it was negative in all Wilms' tumors.
  • CK7 was positive in 20 of 25 papillary RCCs, focally positive in one Wilms' tumor and was negative in all MAs.
  • CD57 was positive in all six MAs that were stained, focally positive in one of 25 papillary RCC and one of eight Wilms' tumors.
  • WT1 was positive in seven of 10 MAs, three of 25 papillary RCCs and all eight Wilms' tumors.
  • In conclusion, diffuse and strong immunoreactivity for AMACR may be useful in differentiating papillary RCC from MA but a panel which includes AMACR, CK7 and CD57 is better in this differential diagnosis.
  • AMACR is not helpful in differentiating MA from Wilms' tumor, but CD57 is helpful in this differential diagnosis.
  • WT1 may be useful in separating Wilms' tumor from MA and papillary RCC but is not helpful in differentiating MA from papillary RCC.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. Kidney Neoplasms / pathology. Racemases and Epimerases / analysis
  • [MeSH-minor] Antigens, CD57 / analysis. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. WT1 Proteins / analysis. Wilms Tumor / enzymology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424894.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / WT1 Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


41. Platell C: Transanal endoscopic microsurgery. ANZ J Surg; 2009 Apr;79(4):275-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transanal endoscopic microsurgery (TEM) is a minimally invasive surgical technique that was developed more than two decades ago to manage distal colorectal neoplasias.
  • The median neoplasia area was 12 cm(2) (IQR, 6-25 cm(2)) and the median height above the anal verge was 9 cm (IQR, 3-17 cm).
  • During a median follow up of 4.2 years (IQR, 2.6-6.2 years), the 5-year cumulative incidence for local recurrence for benign pathology was 3.1% (95% confidence interval (CI): 1.2-6.7%, n = 180) and for cancers managed primarily by TEM excision it was 8.5% (95%CI: 1.4-23.9%, n = 36).
  • TEM is an excellent treatment modality for benign rectal neoplasias of any size, and in any location.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoma in Situ / surgery. Colonoscopy / statistics & numerical data. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Endoscopy, Digestive System. Female. Humans. Male. Microsurgery. Middle Aged. Morbidity. Neoplasm Recurrence, Local / epidemiology. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432714.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


42. Winter H, Lang RA, Spelsberg FW, Jauch KW, Hüttl TP: Laparoscopic colonoscopic rendezvous procedures for the treatment of polyps and early stage carcinomas of the colon. Int J Colorectal Dis; 2007 Nov;22(11):1377-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Endoscopic treatment of large or colonoscopically inaccessible polyps or early stage tumors in the colon holds the risk of incomplete resection and colonic perforation.
  • A benign lesion was confirmed histologically in 31 patients.
  • In five cases, histopathologic diagnosis revealed a malignancy necessitating colonic surgery.
  • CONCLUSION: Rendezvous procedures offer a safe, minimal-invasive therapeutic approach allowing the resection of benign sessile or colonoscopically inaccessible localized polyps and of early stage colon cancer.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / therapy. Colonic Polyps / therapy. Colonoscopy / methods. Laparoscopy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Length of Stay. Male. Middle Aged. Neoplasm Staging. Postoperative Care. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Am Surg. 1988 Feb;54(2):61-3 [3341645.001]
  • [Cites] J Am Coll Surg. 1994 Nov;179(5):513-7 [7952451.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Surg Technol Int. 2003;11:97-101 [12931289.001]
  • [Cites] Dis Colon Rectum. 1994 Aug;37(8):775-6 [7519975.001]
  • [Cites] Ann Intern Med. 1993 Oct 15;119(8):836-43 [8379605.001]
  • [Cites] Surg Laparosc Endosc. 1995 Apr;5(2):137-8 [7773461.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] Dis Colon Rectum. 2001 Jan;44(1):112-8 [11805571.001]
  • [Cites] Surg Laparosc Endosc. 1994 Oct;4(5):382-3 [8000642.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Arch Surg. 2005 Jul;140(7):692-7 [16027336.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Surg Endosc. 1994 Nov;8(11):1352-3 [7831614.001]
  • [Cites] Dis Colon Rectum. 2003 Nov;46(11):1513-6 [14605571.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • [Cites] ANZ J Surg. 2003 Dec;73(12):988-95 [14632888.001]
  • (PMID = 17646999.001).
  • [ISSN] 0179-1958
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


43. Willis S, Schumpelick V: [Open colon surgery]. Chirurg; 2005 Nov;76(11):1073-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In case of benign underlying disease, the operational method depends largely on the extent to which the intestine is affected and can include anything from simple colotomy and polyp removal to colectomy for toxic megacolon.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Lymph Node Excision / methods. Sigmoid Neoplasms / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Colon / pathology. Colonic Polyps / mortality. Colonic Polyps / pathology. Colonic Polyps / surgery. Humans. Neoplasm Invasiveness / pathology. Neoplasm Staging. Postoperative Complications / mortality. Surgical Staplers. Surgical Wound Dehiscence / mortality. Survival Analysis. Suture Techniques

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1988 May;75(5):409-15 [3292002.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] Dis Colon Rectum. 1990 Jul;33(7):610-4 [2361432.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):651-9 [8026230.001]
  • [Cites] Chirurg. 2004 Nov;75(11):1071-8 [15316639.001]
  • (PMID = 16240155.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


44. Shen C, Hu L, Xia L, Li Y: Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn J Clin Oncol; 2008 Nov;38(11):770-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
  • OBJECTIVE: To establish a sensitive method for the early detection of circulating tumor cells (CTCs) in peripheral blood (PB) of colorectal cancer (CRC) patients.
  • METHODS: PB samples were collected from 156 CRC patients, 40 benign colorectal disease patients, 40 healthy individuals and 45 patients with other solid tumors.
  • The expression of the three mRNAs in CRC patients was significantly higher than that in benign control and healthy volunteers, and the expression of survivin and CK20 was not significantly higher than that of patients with other solid tumors.
  • However, the expression of CEA mRNA was significantly higher than that of patients with other solid tumors.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Microtubule-Associated Proteins / blood. Neoplasm Proteins / blood. Neoplastic Cells, Circulating / chemistry. RNA, Messenger / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Cell Line, Tumor. Female. Humans. Inhibitor of Apoptosis Proteins. Keratin-20 / blood. Keratin-20 / genetics. Leukocytes, Mononuclear / chemistry. Leukocytes, Mononuclear / cytology. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845519.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


45. Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J: [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation]. J Radiol; 2009 Sep;90(9 Pt 1):1067-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To review the histological features of 26 circumscribed liver lesions associated with liver capsule retraction and discuss the differential diagnosis while evaluating for the presence of fibrous stromal reaction.
  • RESULTS: Twenty-one patients had benign or malignant liver tumors and 5 patients had confluent hepatic fibrosis.
  • Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1), breast carcinoma (n=1), gallbladder carcinoma (1) and endocrine neoplasm of the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
  • In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary tumor.
  • [MeSH-major] Liver Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2009 Sep;90(9 Pt 1):1019-20 [19752803.001]
  • (PMID = 19752810.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


46. Brosseuk D, Oosthuizen J, Pinchbeck M: Initial experience with a general population colorectal cancer screening clinic. Am J Surg; 2006 May;191(5):669-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with a general population colorectal cancer screening clinic.
  • BACKGROUND: Recognition of adenoma to carcinoma progression has established colorectal cancer as a preventable malignancy.
  • Colorectal cancer is, therefore, an ideal malignancy for preventative screening given the presence of a benign precursor.
  • METHODS: A retrospective chart review of all patients referred to a new low-risk colorectal cancer endoscopic screening clinic from October 1, 2004 to September 30, 2005 was performed.
  • Those patients found to have adenomas or carcinomas were analyzed further regarding location of neoplasm and pathologic findings.
  • RESULTS: A total of 379 low-risk patients attended the colorectal cancer screening clinics.
  • Of the 67 patients with neoplasms, 50 were left of the splenic flexure, 11 were right of the splenic flexure, and 5 patients had lesions both proximal and distal to the flexure.
  • Thirty-two of the 67 patients had complete colonoscopy at the initial procedure and, thus far, 21 patients have had completion colonoscopies, of which 9 patients had further neoplasms identified beyond the splenic flexure.
  • All 3 patients with carcinoma had early tumors resected with curative intent, with negative margins and negative nodes.
  • CONCLUSIONS: Our initial experience with a low-risk general population colorectal cancer endoscopic screening clinic yielded 18% of patients with neoplasms, and 1% had curable cancers resected.
  • [MeSH-major] Cancer Care Facilities. Colonoscopy. Colorectal Neoplasms / diagnosis. Mass Screening / methods
  • [MeSH-minor] Aged. Aged, 80 and over. British Columbia / epidemiology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Video Recording


47. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • The cholecystectomy results in change of cholic acids flow into intestine.
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


48. Rosin D, Zmora O, Hoffman A, Khaikin M, Munz Y, Zakai BB, Goldes Y, Shabtai EL, Shabtai M, Ayalon A: [Laparoscopic colon and rectal surgery--after ten years and 350 operations]. Harefuah; 2007 Mar;146(3):176-80, 247-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present our experience with laparoscopic surgery of the large bowel over the last ten years.
  • RESULTS: Over a period of ten years, 350 various laparoscopic colon and rectal procedures were performed, for both benign and malignant conditions.
  • Sixty percent of the operations were for treatment of colorectal cancer.
  • Five year survival was 56% after resection of colorectal cancer regardless of the stage, and 63% after resection with curative intent.
  • CONCLUSIONS: The laparoscopic approach to large bowel surgery enables short and long term results comparable with those achieved by open technique, regarding perioperative complication rate and long term oncologic outcome.
  • [MeSH-major] Colonic Neoplasms / surgery. Laparoscopy. Rectal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Infection / epidemiology. Infection / mortality. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Postoperative Complications / epidemiology. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17460920.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


49. Endreseth BH, Wibe A, Svinsås M, Mårvik R, Myrvold HE: Postoperative morbidity and recurrence after local excision of rectal adenomas and rectal cancer by transanal endoscopic microsurgery. Colorectal Dis; 2005 Mar;7(2):133-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients with benign pre-operative histopathological examination had cancer.
  • CONCLUSION: TEM is a safe technique well tolerated also by high-risk patients, and should be the preferred method in patients with benign tumours in the middle and upper part of the rectum, and in selected cases of early rectal cancer.
  • Benign pre-operative histology does not preclude malignancy and some patients may need further treatment for unexpected malignancy.
  • [MeSH-major] Adenoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720349.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


50. Wiese D, Saha S, Yestrepsky B, Korant A, Sirop S: A prospective study of false-positive diagnosis of micrometastatic cells in the sentinel lymph nodes in colorectal cancer. Ann Surg Oncol; 2009 Aug;16(8):2166-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of false-positive diagnosis of micrometastatic cells in the sentinel lymph nodes in colorectal cancer.
  • False-positive SLNs occur in breast cancer due to mechanical transport of cells during mapping procedures, or to pre-existing benign cellular inclusions.
  • Our prospective study evaluated whether colorectal mapping procedures alone caused false positives.
  • Ninety of the pts underwent a second mapping in normal bowel away from the primary tumor.
  • The first 1-5 blue nodes near the primary tumor were marked as SLNs; those near the second injection site were marked as nontumor SLNs (nt-SLNs).
  • RESULTS: Of 314 pts, 30 had benign tumor and 284 had invasive cancer.
  • Forty-six of the 274 pts (16.8%) had low-volume metastasis in 57 SLNs: 31 pts (11.3%) had 38 SLNs with micrometastasis (>0.2 mm, <or=2 mm), while 15 pts (5.5%) had 19 SLNs with isolated tumor cells (<or=0.2 mm).
  • For 100 pts with second SLNM (70/90 pts successfully mapped with 102 nt-SLNs), or with SLNM of benign pathology (30/30 pts successfully mapped with 88 SLNs), there were no false positives in any of 190 nodes (P < 0.001).
  • CONCLUSION: No false positives due to mechanical transport of cells or to benign cellular inclusions were identified in 190 lymph nodes from 100 patients with SLNM in benign bowel.
  • [MeSH-major] Colorectal Neoplasms / secondary. Hepatectomy. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] False Positive Reactions. Humans. Keratins / metabolism. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19412630.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


51. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S: Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol; 2009 May;33(5):659-68
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We reviewed histologic material and clinical data from 24 cases selected from a database of 67 dome-based tumors diagnosed and treated at our institution from 1984 to 2005.
  • RESULT: The mean age at diagnosis was 52 years (range: 26 to 68 y).
  • In all instances but 1, cystitis cystica/glandularis was focal and predominantly in the bladder overlying the urachal neoplasm.
  • Urachal remnants were identified in 15 cases: the urachal epithelium was benign urothelial-type in 6 cases and showed adenomatous changes in 9.
  • In all 3, urachal remnants were identified and showed transition from benign to adenomatous epithelium.
  • On immunohistochemistry, these tumors were positive for CK20 and variably positive for CK7 and 34BE12.
  • Surface urothelial involvement by carcinoma and presence of cystitis cystica/glandularis do not necessarily exclude the diagnosis of urachal carcinoma.
  • Immunostains do not unequivocally discriminate a urachal from a colorectal carcinoma, but diffuse positivity for 34BE12 would support, and diffuse nuclear immunoreactivity for beta-catenin would militate against, a diagnosis of urachal carcinoma.
  • Local recurrence may be owing to seeding within the distal urothelial tract, particularly in tumors with a configuration that is polypoid and which open into the bladder cavity.
  • [MeSH-major] Carcinoma / pathology. Urachus / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / pathology. Chemotherapy, Adjuvant. Cystectomy. Cystitis / pathology. Databases as Topic. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome. Umbilicus / surgery. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1380-7 [11684954.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):456-9 [15043458.001]
  • [Cites] J Urol. 1982 Jan;127(1):40-2 [7057501.001]
  • [Cites] Urology. 1983 Apr;21(4):360-6 [6836822.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Urol Res. 1983;11(5):235-8 [6659216.001]
  • [Cites] Urology. 1985 Sep;26(3):218-21 [4035835.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] Hum Pathol. 1996 Mar;27(3):240-7 [8600037.001]
  • [Cites] Cancer. 1955 Jul-Aug;8(4):741-58 [13240656.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):69-87 [16512600.001]
  • [Cites] J Urol. 2006 Jun;175(6):2042-7; discussion 2047 [16697798.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] J Urol. 2007 Jul;178(1):74-8; discussion 78 [17499279.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • (PMID = 19252435.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS627175; NLM/ PMC4225778
  •  go-up   go-down


52. Kabra N, Li Z, Chen L, Li B, Zhang X, Wang C, Yeatman T, Coppola D, Chen J: SirT1 is an inhibitor of proliferation and tumor formation in colon cancer. J Biol Chem; 2009 Jul 3;284(27):18210-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SirT1 is an inhibitor of proliferation and tumor formation in colon cancer.
  • Determination of SirT1 function in tumor cells is important for its targeting in cancer therapy.
  • We found that SirT1 knockdown by short hairpin RNA accelerates tumor xenograft formation by HCT116 cells, whereas SirT1 overexpression inhibits tumor formation.
  • Immunohistochemical staining revealed high level SirT1 in normal colon mucosa and benign adenomas.
  • SirT1 overexpression was observed in approximately 25% of stage I/II/III colorectal adenocarcinomas but rarely found in advanced stage IV tumors.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Feb 17;403(6771):795-800 [10693811.001]
  • [Cites] Science. 2000 Sep 22;289(5487):2126-8 [11000115.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):227-30 [11242085.001]
  • [Cites] Cell. 2001 Oct 19;107(2):137-48 [11672522.001]
  • [Cites] Cell. 2001 Oct 19;107(2):149-59 [11672523.001]
  • [Cites] Nature. 2003 Sep 11;425(6954):191-6 [12939617.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 16;100(19):10794-9 [12960381.001]
  • [Cites] Cell. 2004 Feb 20;116(4):551-63 [14980222.001]
  • [Cites] EMBO J. 2004 Jun 16;23(12):2369-80 [15152190.001]
  • [Cites] Science. 2004 Jul 16;305(5682):390-2 [15205477.001]
  • [Cites] Science. 1990 Jan 19;247(4940):322-4 [2296722.001]
  • [Cites] Cancer Res. 1994 Nov 15;54(22):5947-52 [7954427.001]
  • [Cites] Nature. 2005 Mar 3;434(7029):113-8 [15744310.001]
  • [Cites] Cell Metab. 2005 Jul;2(1):67-76 [16054100.001]
  • [Cites] Cell Metab. 2005 Aug;2(2):105-17 [16098828.001]
  • [Cites] Cell. 2005 Nov 4;123(3):437-48 [16269335.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10457-63 [16288037.001]
  • [Cites] Mol Cell Biol. 2006 Jan;26(1):28-38 [16354677.001]
  • [Cites] Oncogene. 2006 Jan 12;25(2):176-85 [16170353.001]
  • [Cites] PLoS Biol. 2006 Feb;4(2):e31 [16366736.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4368-77 [16618762.001]
  • [Cites] Nat Cell Biol. 2006 Sep;8(9):1025-31 [16892051.001]
  • [Cites] Mol Cell Biol. 2006 Nov;26(21):8122-35 [16923962.001]
  • [Cites] Nature. 2006 Nov 16;444(7117):337-42 [17086191.001]
  • [Cites] Cell. 2006 Dec 15;127(6):1109-22 [17112576.001]
  • [Cites] Mol Cell. 2007 Feb 23;25(4):543-57 [17317627.001]
  • [Cites] Arch Dermatol Res. 2007 May;299(2):103-6 [17180656.001]
  • [Cites] Mol Cell. 2007 Jul 6;27(1):149-62 [17612497.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6612-8 [17638871.001]
  • [Cites] Oncogene. 2007 Aug 13;26(37):5489-504 [17694089.001]
  • [Cites] Biochem J. 2007 Nov 1;407(3):451-60 [17620057.001]
  • [Cites] Biotechnol J. 2007 Nov;2(11):1360-8 [17806102.001]
  • [Cites] Nature. 2007 Nov 29;450(7170):712-6 [18046409.001]
  • [Cites] Mol Biol Cell. 2008 Mar;19(3):1210-9 [18184747.001]
  • [Cites] PLoS One. 2008;3(4):e2020 [18414679.001]
  • [Cites] Cancer Cell. 2008 Oct 7;14(4):312-23 [18835033.001]
  • (PMID = 19433578.001).
  • [ISSN] 1083-351X
  • [Journal-full-title] The Journal of biological chemistry
  • [ISO-abbreviation] J. Biol. Chem.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA112215; United States / NCI NIH HHS / CA / R01 CA112215-03; United States / NCI NIH HHS / CA / CA121291; United States / NCI NIH HHS / CA / R01 CA121291; United States / NCI NIH HHS / CA / CA112215-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / RNA, Small Interfering; EC 3.5.1.- / SIRT1 protein, human; EC 3.5.1.- / Sirtuin 1; EC 3.5.1.- / Sirtuins; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2709385
  •  go-up   go-down


53. Heffernan EJ, Hayes MM, Alkubaidan FO, Clarkson PW, Munk PL: Aggressive angiomyxoma of the thigh. Skeletal Radiol; 2008 Jul;37(7):673-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aggressive angiomyxoma is a rare tumour that typically occurs in the perineum in women of reproductive age.
  • While benign, the tumour is locally infiltrative and consequently has a high rate of local recurrence following surgery; therefore, accurate pre-operative diagnosis is important.
  • We describe a case of aggressive angiomyxoma arising in the thigh of a 54-year-old man, which we believe is the first reported instance of this rare neoplasm occurring remote from the pelvis or perineum in a male patient.
  • At histological analysis, the tumour exhibited the characteristic features of aggressive angiomyxoma, with bland spindle cells and large, hyalinised blood vessels in a hypocellular myxoid matrix.
  • Extensive immunohistochemical staining further supported the diagnosis.
  • While the imaging features of these tumours are non-specific and suggestive of myxoid neoplasms, the diagnosis should be considered whenever biopsy of a myxoid-appearing mass yields hypocellular, non-diagnostic material, despite adequate sampling.
  • [MeSH-major] Magnetic Resonance Imaging. Myxoma / diagnosis. Soft Tissue Neoplasms / diagnosis. Thigh / diagnostic imaging. Thigh / pathology. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):559-63 [12943618.001]
  • [Cites] Int J Gynecol Cancer. 2005 Jan-Feb;15(1):140-5 [15670309.001]
  • [Cites] J Gastroenterol. 2002;37(4):303-8 [11993516.001]
  • [Cites] AJR Am J Roentgenol. 1999 Feb;172(2):435-8 [9930798.001]
  • [Cites] J Clin Pathol. 2000 Aug;53(8):603-5 [11002763.001]
  • [Cites] Int J Urol. 2004 Jun;11(6):432-5 [15157218.001]
  • [Cites] Am J Clin Pathol. 1997 Jan;107(1):45-51 [8980366.001]
  • [Cites] Hum Pathol. 1985 Jun;16(6):621-8 [3997139.001]
  • [Cites] Ann Diagn Pathol. 2006 Aug;10(4):197-204 [16844560.001]
  • [Cites] N Engl J Med. 1999 Dec 2;341(23):1772 [10610453.001]
  • [Cites] Clin Radiol. 2003 Feb;58(2):157-62 [12623047.001]
  • [Cites] Urol Int. 1997;58(4):247-9 [9253128.001]
  • [Cites] AJR Am J Roentgenol. 1998 Aug;171(2):530-1 [9694499.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):396-401 [16445665.001]
  • [Cites] Int J Colorectal Dis. 2007 Dec;22(12):1545-6 [17242939.001]
  • [Cites] Radiology. 2007 Feb;242(2):625-7 [17255431.001]
  • [Cites] Abdom Imaging. 2006 May-Jun;31(3):383-6 [16317491.001]
  • [Cites] Hum Pathol. 2003 Oct;34(10):1072-4 [14608546.001]
  • [Cites] J Oral Maxillofac Surg. 2004 Nov;62(11):1429-31 [15510368.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:356-60 [16515622.001]
  • [Cites] Am J Surg Pathol. 1983 Jul;7(5):463-75 [6684403.001]
  • [Cites] Ultrastruct Pathol. 2006 May-Jun;30(3):193-205 [16825121.001]
  • [Cites] J Clin Ultrasound. 2001 Oct;29(8):476-8 [11745856.001]
  • [Cites] Histopathology. 1997 Jan;30(1):3-10 [9023551.001]
  • [Cites] Cancer. 1996 Jul 1;78(1):79-90 [8646730.001]
  • (PMID = 18338163.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


54. Abouzied MM, Crawford ES, Nabi HA: 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol; 2005 Sep;33(3):145-55; quiz 162-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 18F-FDG PET is emerging as a useful tool in the staging and restaging of many malignant neoplasms, such as lymphoma, lung cancer, colorectal cancer, head and neck cancer, breast cancer, and melanoma.
  • To accurately interpret 18F-FDG findings one must be familiar with the normal physiologic distribution of the tracer, frequently encountered physiologic variants, and benign pathologic causes of 18F-FDG uptake that can be confused with a malignant neoplasm.
  • The objectives of this article are to (a) describe the mechanism of 18F-FDG uptake, (b) list the patient preparation and pertinent patient history before 18F-FDG imaging, (c) describe the whole-body physiologic distribution of 18F-FDG, (d) list and discuss normal physiologic variants, and (e) list and discuss benign pathologic causes of 18F-FDG uptake.
  • [MeSH-major] Artifacts. Diagnostic Errors / prevention & control. Fluorodeoxyglucose F18 / pharmacokinetics. Neoplasms / metabolism. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145222.001).
  • [ISSN] 0091-4916
  • [Journal-full-title] Journal of nuclear medicine technology
  • [ISO-abbreviation] J Nucl Med Technol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 48
  •  go-up   go-down


55. Kadiyska TK, Kaneva RP, Nedin DG, Alexandrova AB, Gegova AT, Lalchev SG, Christova T, Mitev VI, Horst J, Bogdanova N, Kremensky IM: Novel MLH1 frameshift mutation in an extended hereditary nonpolyposis colorectal cancer family. World J Gastroenterol; 2006 Dec 28;12(48):7848-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel MLH1 frameshift mutation in an extended hereditary nonpolyposis colorectal cancer family.
  • AIM: To present novel frameshift mutation c.31delC [p.L11X] in the MLH1 gene identified in an extended Bulgarian hereditary non-polyposis colorectal cancer (HNPCC) family and to analyze the molecular and clinical findings within the pedigree concerning the proposal of adequate individual prophylactic strategy for all mutation carriers.
  • One of the mutation carriers developed a benign giant cell soft tissue tumor.
  • The primary tumor localizations were frequently extracolonic and detailed yearly gastrointestinal and gynecological examinations have been proposed to the mutation carriers.
  • [MeSH-major] Adenocarcinoma / genetics. Carrier Proteins / genetics. Colorectal Neoplasms, Hereditary Nonpolyposis / genetics. Frameshift Mutation / genetics. Nuclear Proteins / genetics. Pedigree
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Bulgaria. DNA, Neoplasm / genetics. Female. Gene Expression Regulation, Neoplastic. Genetic Counseling. Humans. Male. Microsatellite Instability. Middle Aged. MutS Homolog 2 Protein / genetics. Sequence Deletion / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Hereditary Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fam Cancer. 2005;4(3):227-32 [16136382.001]
  • [Cites] Br J Cancer. 2005 Jan 31;92(2):396-404 [15655560.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):208-20 [16434208.001]
  • [Cites] CA Cancer J Clin. 2006 Jul-Aug;56(4):213-25 [16870997.001]
  • [Cites] J Clin Oncol. 2006 Sep 10;24(26):4285-92 [16908935.001]
  • [Cites] Am J Hum Genet. 2001 Jan;68(1):118-127 [11112663.001]
  • [Cites] Hum Mutat. 2002 Jul;20(1):20-7 [12112654.001]
  • [Cites] Mod Pathol. 2002 Jul;15(7):741-9 [12118112.001]
  • [Cites] World J Gastroenterol. 2002 Oct;8(5):837-40 [12378626.001]
  • [Cites] Fam Cancer. 2003;2(1):9-13 [14574162.001]
  • [Cites] Cell. 1993 Dec 3;75(5):1027-38 [8252616.001]
  • [Cites] Nature. 1994 Mar 17;368(6468):258-61 [8145827.001]
  • [Cites] Biochim Biophys Acta. 1999 May 31;1423(3):O1-O10 [10382540.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Dec;155(2):149-51 [15571801.001]
  • [Cites] Fam Cancer. 2005;4(3):233-7 [16136383.001]
  • (PMID = 17203532.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein
  • [Other-IDs] NLM/ PMC4087554
  •  go-up   go-down


56. Somorácz A, Tátrai P, Horváth G, Kiss A, Kupcsulik P, Kovalszky I, Schaff Z: Agrin immunohistochemistry facilitates the determination of primary versus metastatic origin of liver carcinomas. Hum Pathol; 2010 Sep;41(9):1310-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we proved the utility of agrin immumohistochemistry in discriminating between HCCs and benign parenchymal lesions.
  • Here, we have examined the expression of agrin in metastatic liver carcinomas in comparison with primary liver tumors.
  • Immunohistochemistry for agrin was performed on 25 HCC, 16 intrahepatic CCC, 20 colorectal cancer metastasis (CRCm), and 18 pancreatic ductal carcinoma metastasis (PDCm) samples and evaluated with both quantitative and qualitative methods.
  • Regardless of tumor grade, agrin immunostaining was strong in the microvessels of HCCs.
  • As opposed to HCC, agrin immunostaining was faint or nearly absent from the CD34-positive microvessels of CCC, CRCm, and PDCm; rather, it was detected in the basement membranes surrounding tumor cell pseudoglandules.
  • [MeSH-major] Adenoma, Liver Cell / pathology. Agrin / metabolism. Carcinoma, Hepatocellular / pathology. Colorectal Neoplasms / secondary. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Antigens, CD34 / metabolism. Bile Duct Neoplasms / genetics. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / metabolism. Bile Ducts, Intrahepatic / pathology. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Carcinoma, Pancreatic Ductal / genetics. Carcinoma, Pancreatic Ductal / metabolism. Carcinoma, Pancreatic Ductal / secondary. Cholangiocarcinoma / genetics. Cholangiocarcinoma / metabolism. Cholangiocarcinoma / pathology. DNA, Neoplasm / analysis. Diagnosis, Differential. Endothelium, Vascular / metabolism. Endothelium, Vascular / pathology. Female. Gene Expression Regulation, Neoplastic. Hepatectomy. Humans. Male. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. RNA, Messenger / metabolism. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20471664.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Agrin; 0 / Antigens, CD34; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / RNA, Messenger
  •  go-up   go-down


57. van Baardewijk LJ, Idenburg FJ, Clahsen PC, Möllers MJ: [Von Meyenburg complexes in the liver: not metastases]. Ned Tijdschr Geneeskd; 2010;154:A1674
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VMCs, also called biliary hamartomas, are rare and benign malformations of the bile ducts.
  • Intraoperative frozen section analysis to differentiate between malignant and benign lesions has a sensitivity of 97% and a specificity of 99%.
  • The benign nature of VMCs means that they do not require treatment.
  • The patient underwent total mesorectal excision and follow-up after 3, 7 and 9 months did not reveal any indications of recurrent colorectal cancer or metastases.
  • [MeSH-major] Hamartoma / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Aged. Bile Ducts / abnormalities. Bile Ducts / pathology. Carcinoma / pathology. Carcinoma / surgery. Diagnosis, Differential. Female. Humans. Incidental Findings. Liver / pathology. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20619020.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


58. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem; 2009 Sep;55(9):1656-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls.
  • RESULTS: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls.
  • Serum concentrations of DKK1 were decreased significantly in groups of patients with gastric cancer, colorectal cancer, ovarian cancer, and cervical adenocarcinoma compared with healthy controls.
  • DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex.
  • Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .
  • [MeSH-major] Biomarkers, Tumor / blood. Fluoroimmunoassay / methods. Intercellular Signaling Peptides and Proteins / blood. Lung Neoplasms / blood
  • [MeSH-minor] Aged. Calibration. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628661.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


59. Jeong WK, Park JW, Choi HS, Chang HJ, Jeong SY: Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center. Surg Endosc; 2009 Nov;23(11):2575-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery for rectal tumors: experience at Korea's National Cancer Center.
  • BACKGROUND: Transanal endoscopic microsurgery (TEM) is a minimally invasive alternative to transanal excision, enabling complete local excision of selected benign or malignant rectal tumors.
  • This study aimed to determine the surgical and oncologic results for rectal tumors excised by TEM.
  • METHODS: From November 2001 to October 2007, 45 patients underwent TEM for excision of adenoma (13 patients), carcinoid tumor (6 patients), and carcinoma (26 patients).
  • RESULTS: The median tumor distance from the anal verge was 7 cm (range, 3-15 cm), and the median tumor size was 17 mm (range, 2-60 mm).
  • No recurrence occurred for six patients with carcinoid tumors.
  • Histologic examination of the carcinomas showed pathologic tumor (pT) stage 0 (ypT0) in 2 patients, pT1 in 17 patients (including ypT1 in 1 patient), pT2 in 6 patients, and pT3 in 1 patient.
  • CONCLUSIONS: The TEM procedure is a safe and appropriate surgical treatment option for benign rectal tumors.
  • [MeSH-major] Anal Canal / surgery. Microsurgery / methods. Neoplasm Recurrence, Local / pathology. Proctoscopy / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adenoma / mortality. Adenoma / pathology. Adenoma / surgery. Adult. Aged. Cancer Care Facilities. Carcinoid Tumor / mortality. Carcinoid Tumor / pathology. Carcinoid Tumor / surgery. Cohort Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Intestinal Mucosa / surgery. Korea. Male. Middle Aged. Minimally Invasive Surgical Procedures / adverse effects. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Patient Selection. Postoperative Complications / diagnosis. Postoperative Complications / surgery. Reoperation. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Rectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2001 Sep;234(3):352-8; discussion 358-9 [11524588.001]
  • [Cites] Br J Surg. 1996 Feb;83(2):207-10 [8689164.001]
  • [Cites] Chirurg. 1984 Oct;55(10):677-80 [6510078.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1167-72 [15154642.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):880-5 [1914721.001]
  • [Cites] J Clin Oncol. 1989 Aug;7(8):1003-8 [2754446.001]
  • [Cites] Arch Surg. 1998 Aug;133(8):894-9 [9711965.001]
  • [Cites] Surg Endosc. 2007 Jan;21(1):97-102 [17111281.001]
  • [Cites] Surg Endosc. 2003 Aug;17(8):1283-7 [12739119.001]
  • [Cites] Am J Surg. 2007 Nov;194(5):694-8 [17936438.001]
  • [Cites] Ann Surg Oncol. 2006 Apr;13(4):547-56 [16514476.001]
  • [Cites] Dis Colon Rectum. 2008 Jul;51(7):1026-30; discussion 1030-1 [18481147.001]
  • [Cites] Br J Surg. 2005 Dec;92(12):1546-52 [16252312.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):886-92 [8756844.001]
  • [Cites] Am J Clin Oncol. 1994 Oct;17(5):411-6 [8092113.001]
  • [Cites] Colorectal Dis. 2004 Sep;6(5):350-5 [15335369.001]
  • [Cites] World J Surg. 1992 May-Jun;16(3):437-46 [1317077.001]
  • [Cites] Surg Endosc. 2002 Jun;16(6):989-95 [12163970.001]
  • [Cites] Ann Surg Oncol. 2003 Nov;10(9):1106-11 [14597451.001]
  • [Cites] Surg Endosc. 2007 Jun;21(6):970-4 [17285371.001]
  • [Cites] Br J Surg. 2007 May;94(5):627-33 [17335125.001]
  • [Cites] Dis Colon Rectum. 1996 Sep;39(9):969-76 [8797643.001]
  • [Cites] Dis Colon Rectum. 2000 Aug;43(8):1064-71; discussion 1071-4 [10950004.001]
  • [Cites] Arch Surg. 1998 Jun;133(6):595-8; discussion 598-9 [9637456.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):581-5 [16919110.001]
  • [Cites] Dis Colon Rectum. 2005 Feb;48(2):270-84 [15711865.001]
  • (PMID = 19347399.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


60. Cuthbert RJ, Wilson JM, Scott N, Coletta PL, Hull MA: Differential CD74 (major histocompatibility complex Class II invariant chain) expression in mouse and human intestinal adenomas. Eur J Cancer; 2009 Jun;45(9):1654-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Conversely, CD74 protein levels were actually increased in dysplastic epithelial cells in 47/55 (85%) human colorectal adenomas, with CD74 and MIF protein levels together predicting increasing dysplasia in individual adenomas (P=0.003).
  • Down-regulation of CD74 during Apc(Min/+) mouse intestinal tumorigenesis does not model increased CD74 expression at the early, benign stages of human colorectal carcinogenesis.
  • [MeSH-major] Adenoma / immunology. Antigens, Differentiation, B-Lymphocyte / metabolism. Antigens, Neoplasm / metabolism. Colorectal Neoplasms / immunology. Histocompatibility Antigens Class II / metabolism
  • [MeSH-minor] Animals. Down-Regulation / immunology. Gene Expression Regulation, Neoplastic / immunology. Humans. Intramolecular Oxidoreductases / metabolism. Macrophage Migration-Inhibitory Factors / metabolism. Mice. Mice, Inbred C57BL. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Trans-Activators / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19269807.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G116/146; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antigens, Neoplasm; 0 / Histocompatibility Antigens Class II; 0 / Macrophage Migration-Inhibitory Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / Trans-Activators; 0 / invariant chain; EC 5.3.- / Intramolecular Oxidoreductases; EC 5.3.2.1 / MIF protein, human
  •  go-up   go-down


61. Chzhao AV, Kovalenko IuA, Chugunov AO, Novruzbekov MS: [Volume of surgical resection by liver focal lesions]. Khirurgiia (Mosk); 2010;(5):15-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Volume resection by malignant and benign liver lesions was defined, depending on size, localization, number of foci and functional liver reserve.
  • Postoperative lethality of patients with colorectal cancer metastases was 4.3%.
  • Method of surgical treatment depended directly on the tumor stage.
  • Overall and disease-free survival by colorectal cancer metastases was 35.1 and 22.4%, respectively.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Colorectal Neoplasms / mortality. Colorectal Neoplasms / secondary. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20559205.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


62. Clausen OP, Aass HC, Beigi M, Purdie KJ, Proby CM, Brown VL, Mattingsdal M, Micci F, Kølvraa S, Bolund L, Deangelis PM: Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol; 2006 Oct;126(10):2308-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keratoacanthoma (KA) is a benign keratinocytic neoplasm that usually presents as a solitary nodule on sun-exposed areas, develops within 6-8 weeks and spontaneously regresses after 3-6 months.
  • The patterns of recurrent aberrations were also different in the two types of neoplasms, pointing to different genetic mechanisms involved in their developments.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Chromosome Aberrations. Keratoacanthoma / genetics. Nucleic Acid Hybridization / methods. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatology. 1999;199(3):208-12 [10592399.001]
  • [Cites] Br J Dermatol Syph. 1950 Jul-Aug;62(7-8):310-3 [24538027.001]
  • [Cites] Int J Colorectal Dis. 2001 Feb;16(1):38-45 [11317696.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4115-22 [12124350.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):300-3 [12397655.001]
  • [Cites] J Invest Dermatol. 2002 Dec;119(6):1367-72 [12485441.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):876-82 [12873882.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):137-48 [12939741.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):468-75 [14976535.001]
  • [Cites] Br J Surg. 1967 Mar;54(3):191-5 [6020987.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 Jun;7(8):157-63 [5173258.001]
  • [Cites] Australas J Dermatol. 1979 Apr;20(1):34-40 [475695.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Am J Dermatopathol. 1993 Aug;15(4):332-42; discussion 343-52 [8214391.001]
  • [Cites] J Am Acad Dermatol. 1994 Jan;30(1):1-19; quiz 20-2 [8277007.001]
  • [Cites] Arch Dermatol. 1994 Feb;130(2):181-6 [8304756.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4257-60 [8044767.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4756-9 [8062275.001]
  • [Cites] Lancet. 1994 Sep 17;344(8925):788-9 [7916075.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Br J Cancer. 1996 Mar;73(5):649-53 [8605102.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Apr;15(4):234-45 [8703849.001]
  • [Cites] Trends Genet. 1997 Oct;13(10):405-9 [9351342.001]
  • [Cites] Int J Dermatol. 1998 Sep;37(9):677-81 [9762818.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):111-22 [10068200.001]
  • [Cites] J Cutan Pathol. 1999 Apr;26(4):183-9 [10335895.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):526-35 [10408863.001]
  • [Cites] Eur Urol. 2005 Jan;47(1):58-63 [15582250.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):239-48 [15834942.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1250-4 [11245413.001]
  • (PMID = 16728973.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / A6695
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2423224; NLM/ UKMS1915
  •  go-up   go-down


63. Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, Ezzat S, Asa SL: CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene; 2007 Apr 26;26(19):2747-58
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CEACAM1 is a putative tumor suppressor based on diminished expression in some solid neoplasms such as colorectal carcinoma.
  • However, CEACAM1 is overexpressed in some tumors such as non-small cell lung cancer.
  • CEACAM1 is expressed in thyroid carcinoma cell lines derived from tumors that exhibit aggressive behavior.
  • Forced CEACAM1 expression enhanced cell-matrix adhesion and migration and promoted tumor invasiveness.
  • Conversely, small interfering RNA (siRNA)-mediated downregulation of CEACAM1 expression in MRO cells accelerated cell cycle progression and significantly enhanced tumor size in xenografted mice.
  • CEACAM1 is not appreciably expressed in normal thyroid tissue or benign thyroid tumors.
  • In a human thyroid tissue array, CEACAM1 reactivity was associated with metastatic spread but not with increased tumor size.
  • These findings identify CEACAM1 as a unique mediator that restricts tumor growth whereas increasing metastatic potential.
  • [MeSH-major] Antigens, CD / physiology. Carcinoembryonic Antigen / metabolism. Cell Adhesion Molecules / physiology. Cell Proliferation. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Animals. Carcinoma / metabolism. Carcinoma / pathology. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Mice. Mice, SCID. Middle Aged. Neoplasm Invasiveness. RNA, Small Interfering / pharmacology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17057731.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CDKN1A protein, human; 0 / Carcinoembryonic Antigen; 0 / Ceacam1 protein, mouse; 0 / Cell Adhesion Molecules; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


64. Hauenschild L, Bader FG, Laubert T, Czymek R, Hildebrand P, Roblick UJ, Bruch HP, Mirow L: Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy. Int J Colorectal Dis; 2009 Jul;24(7):755-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy.
  • BACKGROUND AND AIMS: Endoscopic polypectomy still remains the cornerstone of therapy for colorectal polyps and adenomas.
  • However, if colorectal polyps are too large or not accessible for endoscopic ablation or cannot be removed without an increased risk for perforation, operative procedures are required.
  • In patients which could not be treated by endoscopic polypectomy due to size, location, and/or risk of complications, a laparoscopic colorectal resection was performed.
  • All data were prospectively assessed in our "colorectal resection" database.
  • RESULTS: The database analysis revealed 58 patients with endoscopically not resectable colorectal polyps who underwent a laparoscopic colorectal resection (intend to treat).
  • The histopathological work-up revealed benign disease in all cases.
  • CONCLUSION: Laparoscopic resection of colorectal polyps is a safe and minimally invasive technique for the management of benign colorectal tumors.
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Colorectal Surgery. Endoscopy. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 2007 Oct;246(4):655-62; discussion 662-4 [17893502.001]
  • [Cites] Arch Surg. 2004 Jan;139(1):39-42 [14718273.001]
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Chirurg. 2003 Oct;74(10):966-80; quiz 981-2 [15017996.001]
  • [Cites] Rev Esp Enferm Dig. 2004 May;96(5):315-21 [15180443.001]
  • [Cites] J Gastrointest Surg. 2009 Feb;13(2):275-81 [18941844.001]
  • [Cites] World J Surg. 2002 Mar;26(3):377-83 [11865378.001]
  • [Cites] Surg Endosc. 1997 Jun;11(6):643-4 [9171124.001]
  • [Cites] Surg Endosc. 2003 Sep;17(9):1461-3 [12739115.001]
  • [Cites] Dis Colon Rectum. 2003 Oct;46(10):1380-3 [14530679.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] Lancet. 2004 Apr 10;363(9416):1187-92 [15081650.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] J Clin Oncol. 2007 Jul 20;25(21):3061-8 [17634484.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s243-7 [15666099.001]
  • [Cites] Cancer. 1989 Nov 1;64(9):1937-47 [2477139.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Br J Surg. 1993 Jun;80(6):788-93 [8330178.001]
  • [Cites] Surg Endosc. 1997 Feb;11(2):119-22 [9069140.001]
  • [Cites] Dis Colon Rectum. 2000 Sep;43(9):1246-9 [11005491.001]
  • [Cites] Lancet. 2002 Jun 29;359(9325):2224-9 [12103285.001]
  • [Cites] Dis Colon Rectum. 2001 May;44(5):746-8 [11357040.001]
  • [Cites] Ann Surg. 2008 Jul;248(1):1-7 [18580199.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s291-4 [15666109.001]
  • [Cites] Onkologie. 2001 Feb;24(1):29-32 [11441277.001]
  • [Cites] Mayo Clin Proc. 2000 Apr;75(4):344-8 [10761487.001]
  • [Cites] Dig Dis. 2005;23(2):127-34 [16352892.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):234-41 [15278051.001]
  • [Cites] Surg Endosc. 2001 Feb;15(2):116-20 [11285950.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 19283390.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


65. Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol; 2007;18(1):16-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goblet cell carcinoid (GCC) of the vermiform appendix is an uncommon neoplasm and its histogenesis is controversial.
  • Little is known about the immunohistochemical expression of cytokeratins 7 (CK7) and 20 (CK20) in appendiceal neuroendocrine tumors.
  • The tumors were also evaluated for Ki-67 proliferation index, mitotic activity, tumor necrosis, extracellular pools of mucin, obvious intestinal type adenocarcinomatous foci, angiolymphatic permeation, perineural/neural infiltration, and the depth of invasion of the appendix wall.
  • Immunohistochemically, all 17 (100%) of GCC exhibited strong and diffuse immunopositivity for CK20, whereas expression of CK7 was present in 12 cases (70.5%), ranging from 5 to 50% of tumor cells being labeled.
  • On the other hand, 25 cases of classical carcinoid tumors were consistently negative for CK7; however, 4 cases (16%) showed immunolabeling for CK20 in 25-50% of the tumor cells.
  • In addition, GCC shows the same CK7/CK20 immunoexpression as colorectal adenocarcinoma.
  • Goblet cell carcinoid should be regarded as a crypt cell or an amphicrine carcinoma rather than a variant of carcinoid tumor, a lesion that has benign connotations.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Carcinoid Tumor / metabolism. Goblet Cells / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):188-9 [7102895.001]
  • [Cites] Br J Surg. 2003 Nov;90(11):1317-22 [14598408.001]
  • [Cites] Differentiation. 1993 Jun;53(2):75-93 [8359595.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Mod Pathol. 2003 Dec;16(12):1189-98 [14681318.001]
  • [Cites] Endocr Pathol. 2002 Spring;13(1):47-58 [12114750.001]
  • [Cites] World J Surg Oncol. 2005 Jun 20;3:36 [15967038.001]
  • [Cites] Am J Surg Pathol. 1981 Apr;5(3):213-24 [7235117.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Oct;19(5):729-38 [16253897.001]
  • [Cites] Am J Surg. 1994 Dec;168(6):685-7 [7978019.001]
  • [Cites] Am Surg. 2004 Jul;70(7):593-9 [15279181.001]
  • [Cites] Histopathology. 1992 Apr;20(4):345-9 [1577412.001]
  • [Cites] Histopathology. 2003 Feb;42(2):137-40 [12558745.001]
  • [Cites] Eur J Surg Oncol. 1992 Aug;18(4):386-7 [1521632.001]
  • [Cites] Ann Surg Oncol. 2006 Mar;13(3):370-6 [16485156.001]
  • [Cites] Surg Today. 2000;30(1):78-81 [10648090.001]
  • [Cites] Cancer. 1979 Nov;44(5):1700-6 [498041.001]
  • [Cites] Ann Anat Pathol (Paris). 1969 Oct-Dec;14(4):393-406 [5378353.001]
  • [Cites] J Clin Pathol. 1995 Sep;48(9):869-70 [7490325.001]
  • [Cites] Cancer. 1974 Aug;34(2):338-44 [4852178.001]
  • [Cites] Arch Pathol Lab Med. 2001 Mar;125(3):386-90 [11231488.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):14-21 [10391558.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2004 Sep;12(3):271-6 [15551743.001]
  • (PMID = 17652796.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7; 0 / Ki-67 Antigen
  •  go-up   go-down


66. Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, Andrews DW, Kenyon L: Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol; 2010;5:46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study explores whether meningioma expresses epidermal growth factor receptor (EGFR) and determines if there is a correlation between the WHO grade of this tumor and the degree of EGFR expression.
  • RESULTS: Eighty-five samples of meningioma were classified in accordance with World Health Organization (WHO) criteria: benign 57/85 (67%), atypical 23/85 (27%), and malignant 5/85 (6%).
  • A significant association was determined when the benign and the atypical samples were compared to the malignant with respect to the SP (p = 0.009).
  • While there was a range of the IHS for the benign and the atypical histologic subtypes, malignant tumors exhibited the lowest score and were statistically different from the benign and the atypical specimens (p < 0.001).
  • EGFR expression is greatest in benign meningiomas and may serve a potential target for therapeutic intervention with selective EGFR inhibitors.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Humans. Immunoenzyme Techniques. Neoplasm Staging. Prognosis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1984 Feb;44(2):753-60 [6318976.001]
  • [Cites] Curr Pharm Des. 2007;13(33):3358-67 [18045190.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Res. 1986 May;46(5):2545-50 [3697993.001]
  • [Cites] Acta Neurochir (Wien). 1986;83(1-2):62-6 [3492089.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] Pol J Pathol. 1998;49(3):145-9 [9810172.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jul;58(7):697-701 [10411339.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):1034-40 [17564176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2139-44 [3052782.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] Cancer Invest. 1991;9(5):553-62 [1933488.001]
  • [Cites] J Endocrinol Invest. 1992 Jan;15(1):31-7 [1560188.001]
  • [Cites] Br J Neurosurg. 1993;7(2):197-9 [8388222.001]
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] J Neurol. 1995 Oct;242(10):683-8 [8568531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):809-15 [8598357.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1284-92 [8826952.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1253-7 [8883413.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):769-74 [9066618.001]
  • [Cites] Neuropeptides. 1997 Jun;31(3):217-25 [9243517.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Acta Oncol. 1998;37(3):285-9 [9677101.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Aug;24(4):427-9 [12905669.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosci Res. 1982;8(2-3):491-507 [6296418.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Lung Cancer. 2007 Aug;57 Suppl 2:S18-23 [17686441.001]
  • [Cites] Expert Opin Pharmacother. 2007 Oct;8(15):2579-92 [17931092.001]
  • [Cites] Clin Colorectal Cancer. 2007 Oct;6 Suppl 2:S42-6 [18021486.001]
  • [Cites] Drugs. 2007;67(17):2585-607 [18034592.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Nov;7(7):650-65 [18045070.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • (PMID = 20509969.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2890616
  •  go-up   go-down


67. Regöly-Mérei A, Bereczky M, Arató G, Telek G, Pallai Z, Lugasi A, Antal M: [Nutritional and antioxidant status of colorectal cancer patients]. Orv Hetil; 2007 Aug 12;148(32):1505-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nutritional and antioxidant status of colorectal cancer patients].
  • INTRODUCTION: Oxidative stress is one of the risk factors of colorectal carcinogenesis.
  • In inflammatory reactions the activated leucocytes product mutagenic and mitogenic free radicals, hereby promoting tumor formation.
  • AIM: Evaluation of some parameters of antioxidant and nutritional status in patients with benign or malignant colorectal neoplasm.
  • RESULTS: In patients with malignant tumor the dietary fiber, folate and vitamin A intake was under the optimal level, and the serum prealbumin concentration was lower than in patients with benign lesion.
  • CONCLUSIONS: The insufficient folate and vitamin A intake, the high incidence of overweight and obesity, and the abnormal values of the biomarkers of antioxidant status observed in the study groups seem to support the correlation between colorectal tumor, nutritional and antioxidant status.
  • [MeSH-major] Adenoma / blood. Antioxidants / metabolism. Carcinoma / blood. Colorectal Neoplasms / blood. Free Radical Scavengers / blood. Nutritional Status

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. VITAMIN A .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675278.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 0 / Free Radical Scavengers; 0 / Prealbumin; 11103-57-4 / Vitamin A; 4Y8F71G49Q / Malondialdehyde; 935E97BOY8 / Folic Acid; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


68. Ducreux M, Dromain C: [Non-invasive imaging tools in colorectal cancer]. Rev Prat; 2010 Oct 20;60(8):1071-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-invasive imaging tools in colorectal cancer].
  • Coloscanner is a new radiologic tool to determine if abnormalities of colon and especially neoplasms are present.
  • In colorectal neoplasm, it is now considered as essential for the diagnosis of unexplained raise of CEA levels, differential diagnosis between benign and malignant disease (especially for suspected local recurrence of rectal cancer), or preoperative staging in case of complex surgical strategies.
  • [MeSH-major] Colorectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21197735.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


69. Davies M, Arumugam PJ, Shah VI, Watkins A, Roger Morgan A, Carr ND, Beynon J: The clinical significance of lymph node micrometastasis in stage I and stage II colorectal cancer. Clin Transl Oncol; 2008 Mar;10(3):175-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of lymph node micrometastasis in stage I and stage II colorectal cancer.
  • The aim of the study was to determine the prevalence and prognostic significance of immunohistochemically detected micrometastasis (IHM) in patients with localised colorectal cancer (CRC) (Dukes' A and B).
  • There was no correlation of IHM with age, gender, site, size and grade of tumour, depth of tumour invasion or perineural and vascular invasion.
  • DISCUSSION: We have shown that isolated CK-positive epithelioid cells are commonly found in morphologically benign pericolic lymph nodes of patients with localised (Dukes' A or B) CRC.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Keratins / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2000 Sep;53(9):685-7 [11041058.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2000 May;12(5):549-52 [10833099.001]
  • [Cites] J R Soc Med. 1992 Jul;85(7):386-8 [1378498.001]
  • [Cites] Ann Surg. 2007 Oct;246(4):568-75; discussion 575-7 [17893493.001]
  • [Cites] Hum Pathol. 1993 Sep;24(9):950-7 [7504652.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1859-61 [2004298.001]
  • [Cites] Eur J Surg Oncol. 2006 Apr;32(3):253-8 [16412600.001]
  • [Cites] J Pathol. 2001 Apr;193(4):442-9 [11276002.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;416(6):479-90 [1692434.001]
  • [Cites] N Engl J Med. 1990 Feb 8;322(6):352-8 [2300087.001]
  • [Cites] Dis Colon Rectum. 1991 Oct;34(10):917-20 [1717210.001]
  • [Cites] J Chemother. 1997 Apr;9(2):119-20 [9176752.001]
  • [Cites] Clin Transl Oncol. 2006 Sep;8(9):676-80 [17005470.001]
  • [Cites] Cancer. 1994 Feb 1;73(3):563-9 [7507795.001]
  • [Cites] Eur J Surg. 1996 Aug;162(8):637-42 [8891622.001]
  • [Cites] Arch Pathol Lab Med. 2000 Sep;124(9):1310-3 [10975928.001]
  • [Cites] Am J Surg Pathol. 2002 Feb;26(2):179-89 [11812939.001]
  • [Cites] Oncology. 1999 Nov;57(4):276-80 [10575311.001]
  • [Cites] J Mol Diagn. 2007 Nov;9(5):563-71 [17916603.001]
  • [Cites] J Pathol. 1994 Feb;172(2):183-7 [7513353.001]
  • [Cites] Dis Colon Rectum. 1997 Dec;40(12):1465-71 [9407986.001]
  • [Cites] Br J Surg. 1990 Mar;77(3):280-2 [1691033.001]
  • (PMID = 18321821.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


70. Gravante G, Delogu D, Venditti D: Colosigmoid adenocarcinoma anastomotic recurrence seeding into a transsphincteric fistula-in-ano: a clinical report and literature review. Surg Laparosc Endosc Percutan Tech; 2008 Aug;18(4):407-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe the case of a left colon adenocarcinoma anastomotic recurrence that metastasized to a benign transsphincteric fistula-in-ano, presumably through the implantation of viable malignant cells shed from the secondary tumor, and discuss the implications of these findings in colorectal cancer surgery.
  • [MeSH-major] Adenocarcinoma / secondary. Neoplasm Recurrence, Local / pathology. Neoplasm Seeding. Rectal Fistula / pathology. Rectal Neoplasms / secondary. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18716545.001).
  • [ISSN] 1534-4908
  • [Journal-full-title] Surgical laparoscopy, endoscopy & percutaneous techniques
  • [ISO-abbreviation] Surg Laparosc Endosc Percutan Tech
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


71. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, Sedlackova E, Lipska L, Stahalova V: The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging; 2006 Jul;33(7):779-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of FDG-PET/CT in the detection of recurrent colorectal cancer.
  • PURPOSE: The conventional diagnostic techniques used to assess recurrence of colorectal cancer (CRCR) often yield unspecific findings.
  • Integrated FDG-PET/CT seems to offer promise for the differential diagnosis of benign and malignant lesions.
  • The sensitivity, specificity and accuracy of PET and PET/CT were calculated for (a) intra-abdominal extrahepatic recurrences, (b) extra-abdominal and/or hepatic recurrences and (c) all recurrences, and tumour marker levels were analysed.
  • Two of these cases were due to increased accumulation in inflammatory foci in the bowel wall, while one was due to haemorrhaging into the adrenal gland.
  • CONCLUSION: FDG-PET/CT appears to be a very promising method for distinguishing a viable tumour from fibrous changes, thereby avoiding unnecessary laparotomy.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Nucl Med. 2005 Apr;46(4):587-95 [15809480.001]
  • [Cites] Eur Radiol. 1998;8(5):781-7 [9601965.001]
  • [Cites] Abdom Imaging. 2000 Sep-Oct;25(5):533-41 [10931993.001]
  • [Cites] J Clin Oncol. 1999 Mar;17 (3):894-901 [10071281.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4357-68 [15514377.001]
  • [Cites] Radiol Clin North Am. 2004 Nov;42(6):1123-39, ix [15488562.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1784-8 [14602860.001]
  • [Cites] J Nucl Med. 1997 Aug;38(8):1196-201 [9255148.001]
  • [Cites] Abdom Imaging. 2004 Nov-Dec;29(6):663-8 [15162236.001]
  • [Cites] Radiology. 2004 Aug;232(2):335-46 [15286305.001]
  • [Cites] Radiology. 2004 Sep;232(3):815-22 [15273334.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] Eur J Nucl Med. 2001 Nov;28(11):1707-23 [11702115.001]
  • [Cites] Dis Colon Rectum. 2002 Aug;45(8):1078-84 [12195193.001]
  • [Cites] Colorectal Dis. 2003 Sep;5(5):496-500 [12925088.001]
  • [Cites] Radiology. 1989 Feb;170(2):323-8 [2911656.001]
  • (PMID = 16565845.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


72. Kim J, Roh M, Abdulkadir SA: Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer; 2010 Jun 01;10:248
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The serine/threonine kinase PIM1 has been implicated as an oncogene in various human cancers including lymphomas, gastric, colorectal and prostate carcinomas.
  • However, there has been limited analysis of the tumorigenic potential of Pim1 overexpression in benign and malignant human prostate cancer cells in vivo.
  • METHODS: We overexpressed Pim1 in three human prostate cell lines representing different disease stages including benign (RWPE1), androgen-dependent cancer (LNCaP) and androgen-independent cancer (DU145).
  • RESULTS: Overexpression of Pim1 alone was not sufficient to convert the benign RWPE1 cell to malignancy although it enhanced their proliferation rates when grown as xenografts in vivo.
  • Reporter assays revealed increased c-MYC transcriptional activity in Pim1-expressing cells and mRNA expression profiling demonstrated that a large fraction of c-MYC target genes were also regulated by Pim1 expression.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 May 1;60(9):2335-41 [10811103.001]
  • [Cites] Exp Hematol. 2006 Nov;34(11):1480-9 [17046567.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Chromosoma. 2002 Jul;111(2):80-95 [12111331.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 16;1593(1):45-55 [12431783.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1833-41 [12714522.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1301-9 [13679438.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6151-9 [13679853.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8079-84 [14678956.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1869-75 [14592832.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1838-44 [14981536.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):367-71 [15264249.001]
  • [Cites] FEBS Lett. 2004 Jul 30;571(1-3):43-9 [15280015.001]
  • [Cites] Cancer Res. 1977 Nov;37(11):4049-58 [908039.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Prog Clin Biol Res. 1980;37:115-32 [7384082.001]
  • [Cites] Prog Clin Biol Res. 1980;37:67-84 [7384095.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;105(1):20-3 [6833336.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5228-34 [6616459.001]
  • [Cites] Cell. 1989 Feb 24;56(4):673-82 [2537153.001]
  • [Cites] Nature. 1989 Jul 6;340(6228):61-3 [2786994.001]
  • [Cites] Oncogene. 1991 Nov;6(11):1941-8 [1658705.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1215-23 [9214605.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18659-66 [10373478.001]
  • [Cites] Anticancer Drugs. 2007 Feb;18(2):161-70 [17159602.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):932-44 [17643117.001]
  • [Cites] Mol Cancer Ther. 2007 Sep;6(9):2399-408 [17876039.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5076-85 [18593906.001]
  • [Cites] PLoS One. 2008;3(7):e2572 [18596907.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4809-19 [18438430.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2144-51 [18715779.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25 [18509642.001]
  • [Cites] PLoS Genet. 2009 Jul;5(7):e1000542 [19578399.001]
  • [Cites] Oncogene. 2009 Dec 3;28(48):4261-71 [19749799.001]
  • [Cites] Oncogene. 2010 Apr 29;29(17):2477-87 [20140016.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48319-28 [15319445.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):6130-7 [15525646.001]
  • [Cites] J Pathol. 2005 May;206(1):87-91 [15809970.001]
  • [Cites] Mol Cancer Res. 2005 Aug;3(8):443-51 [16123140.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40568-77 [16221667.001]
  • [Cites] Leukemia. 2006 Mar;20(3):539-42 [16437153.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):285-8 [16505280.001]
  • [Cites] Nat Med. 2001 Jan;7(1):101-7 [11135623.001]
  • (PMID = 20515470.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA123484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; 0 / AR protein, human; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Thiazoles; EC 2.7.11.1 / Proto-Oncogene Proteins c-pim-1
  • [Other-IDs] NLM/ PMC2886047
  •  go-up   go-down


73. Salama M, Ormonde D, Quach T, Ee H, Yusoff I: Outcomes of endoscopic resection of large colorectal neoplasms: an Australian experience. J Gastroenterol Hepatol; 2010 Jan;25(1):84-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of endoscopic resection of large colorectal neoplasms: an Australian experience.
  • BACKGROUND AND AIMS: Endoscopic resection of large colorectal neoplasms is increasingly being used as an alternative to surgery.
  • The aim of the study was to report short- and long-term outcomes from endoscopic resection of large colorectal neoplasms from a single centre and use a model to predict mortality had surgery been performed.
  • METHODS: Consecutive patients referred for endoscopic resection of large (> or = 20 mm) colorectal neoplasms from January 2001 to February 2008 were included.
  • The Colorectal-POSSUM score was used to estimate mortality from open surgery.
  • RESULTS: There were 154 large neoplasms in 140 patients.
  • Mean neoplasm size was 26 mm (range 20-80 mm, 24 > or = 40 mm).
  • CONCLUSION: Endoscopic resection of large colorectal neoplasms is safe and effective even for very large benign neoplasms.
  • [MeSH-major] Colectomy. Colonoscopy. Colorectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793173.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


74. Sasaki A, Nitta H, Otsuka K, Takahara T, Nishizuka S, Wakabayashi G: Ten-year experience of totally laparoscopic liver resection in a single institution. Br J Surg; 2009 Mar;96(3):274-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between May 1997 and April 2008, 82 patients underwent TLLR for hepatocellular carcinoma (HCC) (37 patients), liver metastases (39) and benign liver lesions (six).
  • Nine patients underwent simultaneous laparoscopic resection of colorectal primary cancer and synchronous liver metastases.
  • Median tumour size and surgical margin were 25 (range 15-85) and 6 (range 0-40) mm respectively.
  • The overall 5-year survival rate after surgery for HCC and colorectal metastases was 53 and 64 per cent respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Laparoscopy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Complications / etiology. Length of Stay. Liver Diseases / surgery. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications / etiology. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224518.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


75. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A; 2008 Mar 18;105(11):4283-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative lesion sequencing provides insights into tumor evolution.
  • We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common.
  • When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize;.
  • (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells.
  • These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 [18089773.001]
  • [Cites] World J Surg. 2004 Mar;28(3):263-70 [14961200.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Humangenetik. 1972;16(1):87-110 [4647448.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):773-81 [7171456.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1650-5 [6299526.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6109-14 [3167857.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):968-71 [2159442.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):60-6 [1998868.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):435-41 [7640229.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cytometry. 1997 Nov 1;29(3):273-8 [9389445.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):213-22 [9748584.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):803-11 [10091757.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):292-6 [10336810.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1963 Oct;90:673-87 [14068399.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8111-7 [16166284.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):610-4 [16582617.001]
  • [Cites] Cancer Sci. 2006 May;97(5):362-7 [16630132.001]
  • [Cites] Nat Methods. 2006 Jul;3(7):551-9 [16791214.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227 [17178965.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):R233-6 [17407749.001]
  • [Cites] Nat Protoc. 2006;1(2):859-69 [17406318.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11471-5 [18089772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 [12857956.001]
  • (PMID = 18337506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R01 CA127306; United States / NCI NIH HHS / CA / CA121113; United States / NIGMS NIH HHS / GM / GM078986; United States / NCI NIH HHS / CA / CA127306; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIGMS NIH HHS / GM / R01 GM078986; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R01 CA120237; United States / NCI NIH HHS / CA / R01 CA121113; United States / NIGMS NIH HHS / GM / GM078986-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043703; United States / NCI NIH HHS / CA / CA120237; United States / NCI NIH HHS / CA / U54 CA116867; United States / NIGMS NIH HHS / GM / R01 GM078986-02; United States / NCI NIH HHS / CA / CA116867; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA105090
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2393770
  •  go-up   go-down


76. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • OBJECTIVE: To estimate the frequency of extrapancreatic neoplasms in patients with IPMN compared with those with ductal pancreatic cancer and a general referral population.
  • SUMMARY BACKGROUND DATA: Several studies have reported an increased risk of extrapancreatic neoplasms in patients with IPMN, but these studies focused only on those patients who underwent resection and excluded those patients treated nonoperatively.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • Logistic regression was used to assess the risk of a diagnosis of extrapancreatic neoplasms among cases versus controls.
  • The proportion of IPMN patients having any extrapancreatic neoplasm diagnosed before or coincident to the index date was 52% (95% CI, 47%-56%), compared with 36% (95% CI, 32%-41%) in Group 1 (P < 0.001), and 43% (95% CI, 41%-46%) in Group 2 (P = 0.002).
  • Benign neoplasms most frequent in the IPMN group were colonic polyps (n = 114) and Barrett's neoplasia (n = 18).
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • CONCLUSIONS: Patients with IPMN have increased risk of harboring extrapancreatic neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


77. Huang ZH, Li LH, Yang F, Wang JF: Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions. World J Gastroenterol; 2007 Feb 14;13(6):950-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of aberrant methylation in fecal DNA as a molecular screening tool for colorectal cancer and precancerous lesions.
  • AIM: To investigate the feasibility of detecting methylated fecal DNA as a screening tool for colorectal carcinoma (CRC) and precancerous lesions.
  • METHODS: Methylated secreted frizzled-related protein gene 2 (SFRP2), hyperplastic polyposis protein gene (HPP1) and O6-methylguanine-DNA methyltransferase gene (MGMT) in stools from 52 patients with CRC, 35 patients with benign colorectal diseases and 24 normal individuals were analyzed using methylation-specific PCR.
  • [MeSH-major] Adenoma / diagnosis. Carcinoma / diagnosis. Colorectal Neoplasms / diagnosis. DNA Methylation. DNA, Neoplasm / analysis. Feces / chemistry. Precancerous Conditions / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Biomarkers, Tumor / genetics. DNA Modification Methylases / genetics. DNA Repair Enzymes / genetics. Female. Humans. Male. Membrane Proteins / genetics. Middle Aged. Molecular Sequence Data. Neoplasm Proteins / genetics. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):265-70 [11120884.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6820-2 [12460892.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):778-96 [12817424.001]
  • [Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):29-39 [15000147.001]
  • [Cites] Gut. 2004 Apr;53(4):573-80 [15016754.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Sep;13(9):1495-501 [15342451.001]
  • [Cites] Clin Chem. 2004 Nov;50(11):2179-82 [15502094.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Feb;3(2):142-9 [15704048.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):907-15 [16152625.001]
  • [Cites] Nat Rev Cancer. 2006 Feb;6(2):107-16 [16491070.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • (PMID = 17352030.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / Neoplasm Proteins; 0 / SFRP2 protein, human; 0 / TMEFF2 protein, human; 0 / Tumor Suppressor Proteins; EC 2.1.1.- / DNA Modification Methylases; EC 2.1.1.63 / MGMT protein, human; EC 6.5.1.- / DNA Repair Enzymes
  • [Other-IDs] NLM/ PMC4065936
  •  go-up   go-down


78. Kumar S, Fitzmaurice GJ, O'Donnell ME, Brown R: Acute right iliac fossa pain: not always appendicitis or a caecal tumour: two case reports. Cases J; 2009;2(1):88
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute right iliac fossa pain: not always appendicitis or a caecal tumour: two case reports.
  • BACKGROUND: A solitary diverticulum of the caecum is a rare benign condition which was first described by Potier in 1912 1.
  • Despite radiological imaging, a pre-operative diagnosis is infrequent.
  • We discuss the clinical presentation, investigative modalities, and current therapeutic guidelines associated with this rare condition and highlight the difference from the more common conditions of appendicitis in the young and caecal neoplasms in the older patient.
  • CONCLUSION: Complications of a solitary caecal diverticulum should be considered in the differential diagnosis of acute right lower quadrant pain.
  • The presence of multiple diverticula, caecal phlegmon, or the inability to rule out an underlying caecal neoplasm warrants a right hemicolectomy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Enferm Dig. 2006 Nov;98(11):875-80 [17198478.001]
  • [Cites] Ann R Coll Surg Engl. 2006 Nov;88(7):672-4 [17132320.001]
  • [Cites] Ulster Med J. 2005 Sep;74(2):132-3 [16235768.001]
  • [Cites] Ann Chir Gynaecol Suppl. 1977;66(5):230-3 [413467.001]
  • [Cites] J Am Coll Surg. 1999 Jun;188(6):629-34; discussion 634-5 [10359355.001]
  • [Cites] Am Surg. 1987 Jan;53(1):41-5 [3099619.001]
  • [Cites] Dis Colon Rectum. 1978 Nov-Dec;21(8):627-9 [104852.001]
  • [Cites] Tech Coloproctol. 2004 Nov;8 Suppl 1:s116-8 [15655592.001]
  • (PMID = 19173712.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2637256
  •  go-up   go-down


79. Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM: Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol; 2007 Mar;20(3):375-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer.
  • Aberrant expression of human leukocyte antigen G (HLA-G) has been proposed to be involved in tumor escape mechanisms.
  • It has been also proposed that detection of HLA-G might service as a potential biomarker for diagnosis or prediction of the clinical outcomes in ovarian and breast cancers, carcinoma of the lung and endometrial cancer.
  • The aim of this current study is to determine if HLA-G is expressed in colorectal carcinomas and if the expression is associated with clinicopathological and prognostic data.
  • The expression of HLA-G was investigated immunohistochemically in 201 patients with colorectal carcinomas.
  • In this prospectively study, HLA-G protein expression was observed in 64.6% (130/201) of the primary site colorectal carcinomas, but not in the normal colorectal tissues or benign adenomas.
  • HLA-G expression in the tumors was significantly correlated with the depth of invasion, histological grade, host immune response, lymph nodal metastasis and clinical stages of the disease (P=0.001, 0.0001, 0.002, 0.001 and 0.031, respectively).
  • Patients with HLA-G positive tumors had a significantly shorter survival time than those patients with tumors that were HLA-G negative (P=0.0001).
  • Therefore, it can be gathered that HLA-G might serve as an independent prognostic factor for colorectal cancer patients.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis
  • [MeSH-minor] Female. HLA-G Antigens. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Prognosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277760.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


80. Remzi FH, Kirat HT, Geisler DP: Laparoscopic single-port colectomy for sigmoid cancer. Tech Coloproctol; 2010 Sep;14(3):253-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Laparoscopic single-port sigmoid colectomy through a 3-cm umbilical incision was performed on a patient with a diagnosis of sigmoid cancer.
  • Colonoscopy performed 1 year after surgery showed no neoplasm or polyp identified.
  • CONCLUSION: Single-port laparoscopic surgery may allow common benign procedures via an incision in the umbilicus.
  • It can also be performed with good surgical and oncologic results in selected patients with a colorectal cancer.
  • [MeSH-major] Laparoscopy / methods. Sigmoid Neoplasms / pathology. Sigmoid Neoplasms / surgery. Umbilicus / surgery
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Length of Stay. Middle Aged. Neoplasm Staging. Pain, Postoperative. Sigmoidoscopy / methods. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2005 Jul;6(7):477-84 [15992696.001]
  • [Cites] Ann Surg. 2009 Apr;249(4):596-601 [19300230.001]
  • [Cites] Colorectal Dis. 2008 Oct;10(8):823-6 [18684153.001]
  • [Cites] Surg Endosc. 2002 May;16(5):833-5 [11997832.001]
  • [Cites] Arch Surg. 2007 Sep;142(9):823-6; discussion 826-7 [17875836.001]
  • [Cites] Eur J Surg. 1999 Jan;165(1):29-34 [10069631.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 1999 Aug;9(4):361-4 [10488834.001]
  • [Cites] Ann Surg. 2009 Jan;249(1):77-81 [19106679.001]
  • [Cites] BJU Int. 2008 Jan;101(1):83-8 [18086101.001]
  • [Cites] Dis Colon Rectum. 2009 Apr;52(4):558-66 [19404053.001]
  • [Cites] Surg Endosc. 2003 May;17(5):828-30 [12582763.001]
  • [Cites] Urology. 2008 Jan;71(1):3-6 [18242353.001]
  • [Cites] Endoscopy. 2007 Oct;39(10):913-5 [17968809.001]
  • [Cites] Arch Surg. 2009 Feb;144(2):173-9; discussion 179 [19221330.001]
  • (PMID = 19953288.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


81. Nonose R, Priolli DG, Cardinalli IA, Máximo FR, Galvão PS, Martinez CA: Epithelioid hemangioma of the colon: a case report. Sao Paulo Med J; 2008 Sep;126(5):294-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONTEXT: Epithelioid hemangioma or angiolymphoid hyperplasia with eosinophilia is an uncommon benign vascular neoplasm that is usually located on the face or neck.
  • Neoplasia of the colon was clinically suspected and she underwent colonoscopy.
  • A biopsy collected during the examination suggested a diagnosis of neoplasia of vascular origin.
  • After surgical resection, histopathological examination of the resected specimen confirmed the diagnosis of epithelioid hemangioma of the colon, which was backed up by the immunohistochemical panel (factor VIII, Ki-67, CD-34).
  • Despite the rarity of neoplasia of vascular origin, this possibility should be considered in the differential diagnosis for colorectal tumors.
  • [MeSH-major] Angiolymphoid Hyperplasia with Eosinophilia / pathology. Colon / pathology. Hemangioma / pathology. Sigmoid Neoplasms / pathology
  • [MeSH-minor] Abdominal Pain. Adult. Colonoscopy. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Hemangioma.
  • MedlinePlus Health Information. consumer health - Birthmarks.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19099166.001).
  • [ISSN] 1806-9460
  • [Journal-full-title] São Paulo medical journal = Revista paulista de medicina
  • [ISO-abbreviation] Sao Paulo Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


82. Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res; 2005 Feb 1;11(3):1203-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps.
  • Most colon cancers arise from benign neoplasms and evolve into adenocarcinomas through a stepwise histologic progression sequence that starts from adenomas or hyperplastic polyps/serrated adenomas.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA Methylation. DNA, Neoplasm / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenoma / genetics. Adenoma / pathology. Carrier Proteins. Cell Line, Tumor. CpG Islands / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Feces / chemistry. Humans. Hyperplasia. Neoplasm Proteins / genetics. Nuclear Proteins. O(6)-Methylguanine-DNA Methyltransferase / genetics

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15709190.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA 95103; United States / NCI NIH HHS / CA / U01 CA 094986
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA, Neoplasm; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  •  go-up   go-down


83. Grossmann I, Avenarius JK, Mastboom WJ, Klaase JM: Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure. Ann Surg Oncol; 2010 Aug;17(8):2045-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure.
  • BACKGROUND: Preoperative staging of patients with colorectal carcinoma (CRC) has the potential benefit of altering treatment options when metastases are present.
  • MATERIALS AND METHODS: All patients who undergo colorectal surgery in our hospital are prospectively registered, including patient, treatment, and histopathological characteristics; outcome; and follow-up.
  • These were diagnosed during follow-up as true metastases (n = 8), bronchus carcinoma (n = 2), benign lesions (n = 25), and remaining unknown (n = 15).
  • In none of the patients the treatment plan for the primary tumor was changed based on the staging chest CT.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Neoplasm Staging / methods. Preoperative Care. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2007 Jul-Aug;31(4):569-71 [17882033.001]
  • [Cites] Onkologie. 2007 Mar;30(3):141-5 [17341902.001]
  • [Cites] Ann R Coll Surg Engl. 2007 Nov;89(8):744-8 [17999813.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1026-32 [19184237.001]
  • [Cites] Colorectal Dis. 2009 Jul;11(6):592-600 [18624816.001]
  • [Cites] Colorectal Dis. 2007 Nov;9(9):816-8 [17931171.001]
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 May;21(5):906-12 [12062285.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):9-15 [9524701.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):229-35 [10421258.001]
  • [Cites] Annu Rev Med. 2005;56:139-56 [15660506.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Jan;53(1):22-8 [15724498.001]
  • [Cites] Ann R Coll Surg Engl. 2005 Sep;87(5):331-3 [16176690.001]
  • [Cites] Radiat Med. 2005 Sep;23(6):418-26 [16389984.001]
  • [Cites] Surgery. 2007 Jan;141(1):67-75 [17188169.001]
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S224-5; author reply S226-7 [20839065.001]
  • (PMID = 20151212.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2899025
  •  go-up   go-down


84. Belinsky GS, Claffey KP, Nambiar PR, Guda K, Rosenberg DW: Vascular endothelial growth factor and enhanced angiogenesis do not promote metastatic conversion of a newly established azoxymethane-induced colon cancer cell line. Mol Carcinog; 2005 Jun;43(2):65-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The organo-specific carcinogen, azoxymethane (AOM), produces colon tumors in mice that share many pathological features with sporadic human colorectal cancer (CRC).
  • To assess the role of the microenvironment in preventing the invasive phenotype, multiple benign in situ adenocarcinomas were harvested from AOM-treated mice and cultured in vitro.
  • However, tumor cell growth was extremely limiting under standard culturing conditions.
  • Thus, we injected tumor cells directly into nude mice and performed two serial transplants, and successfully explanted a rapidly growing epithelial tumor cell line (AJ02nm(0)).
  • When injected subcutaneously (sc) into nude mice, AJ02nm(0) cells formed well-differentiated adenocarcinomas with minimal tumor invasive capacity.
  • AJ02nm-VEGF cells produced rapidly growing tumors in nude mice that exhibited extensive pseudo-epithelial ductal architecture and supporting vasculature, but without increased invasive potential compared to controls.
  • [MeSH-major] Colonic Neoplasms / blood supply. Neovascularization, Pathologic / physiopathology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Animals. Antigens, CD31 / analysis. Apoptosis. Cell Division. Cell Line, Tumor. Colorectal Neoplasms / blood supply. Colorectal Neoplasms / pathology. Karyotyping. Male. Mice. Mice, Inbred A. Mice, Nude. Neoplasm Transplantation. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15768385.001).
  • [ISSN] 0899-1987
  • [Journal-full-title] Molecular carcinogenesis
  • [ISO-abbreviation] Mol. Carcinog.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA 81428
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


85. Øgreid D, Hamre E: Stool DNA analysis detects premorphological colorectal neoplasia: a case report. Eur J Gastroenterol Hepatol; 2007 Aug;19(8):725-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stool DNA analysis detects premorphological colorectal neoplasia: a case report.
  • Colorectal cancers usually develop from benign adenomas in a lengthy period of 5-10 years.
  • Our patient did not present any signs or symptoms of colorectal disease during his two visits to the endoscopist.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. DNA, Neoplasm / analysis. Feces / chemistry. Precancerous Conditions / diagnosis
  • [MeSH-minor] Colonic Polyps / diagnosis. Genetic Markers. Humans. Male. Middle Aged. Mutation. Neoplastic Syndromes, Hereditary / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625445.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


86. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • This finding supports the practice of performing oncological resection for all patients with endoscopically unresectable neoplasms of the colorectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2004 May 13;350(20):2050-9 [15141043.001]
  • [Cites] Am J Surg. 1999 May;177(5):384-7 [10365875.001]
  • [Cites] Ann Surg. 1979 Dec;190(6):679-83 [518167.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1341-4 [9788858.001]
  • [Cites] AORN J. 1992 Dec;56(6):1068-73 [1463326.001]
  • [Cites] Dis Colon Rectum. 2006 Jun;49(6):879-82 [16598402.001]
  • [Cites] Surg Endosc. 2005 Sep;19(9):1252-5 [16132333.001]
  • [Cites] Surg Endosc. 2007 Mar;21(3):400-3 [17180271.001]
  • [Cites] Int J Colorectal Dis. 1997;12(5):267-71 [9401839.001]
  • [Cites] Br J Surg. 1999 Apr;86(4):505-8 [10215825.001]
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Fujii H, Jiang W, Matsumoto T, Miyai K, Sashara K, Ohtsuji N, Hino O: Birt-Hogg-Dubé gene mutations in human endometrial carcinomas with microsatellite instability. J Pathol; 2006 Jul;209(3):328-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé (BHD) syndrome is a rare form of autosomal dominantly inherited genodermatosis characterized by benign hamartomatous skin lesions named fibrofolliculomas, and an increased risk for developing pulmonary cyst/pneumothorax and various forms of renal cell carcinoma.
  • This mutational hot spot is also reported to be a target of mutation in microsatellite instability (MSI) sporadic colorectal cancer.
  • Of these, one showed additional mutation in exon 4, possibly satisfying the two-hit hypothesis of tumour suppressor genes.
  • When multiple foci were microdissected and individually screened for mutation, BHD mutations were shown to have been acquired during tumour progression, after mutation of the BAX gene, in three of five cases.
  • [MeSH-major] Endometrial Neoplasms / genetics. Microsatellite Repeats / genetics. Mutation. Neoplastic Syndromes, Hereditary / genetics. Proteins / genetics. Proto-Oncogene Proteins / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adult. Aged. Aged, 80 and over. Base Sequence. Carrier Proteins / genetics. DNA Methylation. DNA-Binding Proteins / genetics. Disease Progression. Female. Humans. Microdissection / methods. Middle Aged. Molecular Sequence Data. Neoplasm Proteins / genetics. Nuclear Proteins / genetics. bcl-2-Associated X Protein / genetics

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Pathological Society of Great Britain and Ireland.
  • (PMID = 16691634.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / FLCN protein, human; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein
  •  go-up   go-down


88. Inbar R, Greenberg R, Nir S, Shmueli E, Scornick Y, Avital S: [Three hundred laparoscopic colorectal operations--safety, levels of difficulty and survival]. Harefuah; 2010 Aug;149(8):498-502, 552, 551
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three hundred laparoscopic colorectal operations--safety, levels of difficulty and survival].
  • INTRODUCTION: The accumulated data in recent years on the safety of laparoscopy in colorectal cancer patients encourage more surgeons to use this approach for different colorectal pathologies.
  • However, laparoscopic colorectal surgery consists of different heterogeneous complex procedures that necessitate extensive experience and laparoscopic surgical skills PURPOSE: To evaluate safety, levels of difficulty and oncological outcome in a consecutive series of patients that underwent elective laparoscopic colorectal surgery during a 5-year period.
  • METHODS: Evaluation of our prospective collected data of patients that underwent laparoscopic colorectal surgery during a 5-year period by our surgical team.
  • Indications for surgery included cancer (58%), benign polyps (16%), Crohn's disease (6%), diverticular disease (10%) and others (10%).
  • A total of 171 patients underwent operations for curable colorectal cancer.
  • CONCLUSIONS: Laparoscopic colorectal surgery is safe.
  • Immediate oncological results and 2-year survival in colorectal cancer patients, as demonstrated in our study, are adequate and comparable to the open approach.
  • The authors believe that adequate results in laparoscopic colorectal operations can be achieved by a dedicated laparoscopic colorectal team.
  • [MeSH-major] Colorectal Neoplasms / surgery. Intestinal Diseases / surgery. Laparoscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Elective Surgical Procedures / adverse effects. Elective Surgical Procedures / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / etiology. Prospective Studies. Reoperation. Surgical Wound Infection / epidemiology. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21341427.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


89. Schmidt MB, Engel UH, Mogensen AM, Petersen LN, Bülow S, Wied U, Holck S, Danish Colorectal Cancer Group: [Resection time and number of detected colorectal lymph nodes in resection specimens with carcinoma]. Ugeskr Laeger; 2009 Aug 24;171(35):2458-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resection time and number of detected colorectal lymph nodes in resection specimens with carcinoma].
  • INTRODUCTION: The number of identified lymph nodes (LNs) is an essential element in the pathologist's rapport on colorectal resection specimens with carcinoma (CRSC).
  • Provided this careful analysis failed to produce 12 LNs and all detected LNs were benign (pNx), the specimen was re-sampled for an additional 15-minute period.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Humans. Neoplasm Staging. Prospective Studies. Specimen Handling. Time Factors

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732530.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


90. Ma TL, Ni PH, Zhong J, Tan JH, Qiao MM, Jiang SH: Low expression of XIAP-associated factor 1 in human colorectal cancers. Chin J Dig Dis; 2005;6(1):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low expression of XIAP-associated factor 1 in human colorectal cancers.
  • The aims of the present study were: (i) to investigate the expression of XAF1 in human colorectal cancers (CRC) both in vitro and in vivo, and (ii) to evaluate the possibility of XAF1 as a new tumor marker.
  • The expression of XAF1 in tissue was relatively lower in primary CRC compared with a relatively higher level in benign colorectal tumors (P < 0.01).
  • Although the XAF1 expression in circulation of those with CRC was also lower than in those with benign tumors, there was no statistical significance (P > 0.05).
  • CONCLUSIONS: The present results suggest that the low expression of XAF1 in tumor tissue coincides with a similar level in the peripheral circulation, which contributes at least part to the malignant behavior of CRC.
  • Integrating the XAF1 relative expression value with the other three traditional tumor biomarkers created a four-parameter assay that significantly improved the rate of diagnosis of CRC.
  • [MeSH-major] Biomarkers, Tumor / blood. Colonic Neoplasms / genetics. Colonic Neoplasms / physiopathology. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Aged. Apoptosis. Case-Control Studies. Female. Gene Expression Profiling. Humans. Intracellular Signaling Peptides and Proteins. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured. Zinc Fingers

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15667552.001).
  • [ISSN] 1443-9611
  • [Journal-full-title] Chinese journal of digestive diseases
  • [ISO-abbreviation] Chin J Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Intracellular Signaling Peptides and Proteins; 0 / Neoplasm Proteins; 0 / XAF1 protein, human
  •  go-up   go-down


91. Koch M, Kienle P, Logan E, Antolovic D, Galindo L, Schmitz-Winnenthal FH, Schmidt J, Herfarth C, Weitz J: Detection of disseminated tumor cells in liver biopsies of colorectal cancer patients is not associated with a worse prognosis. Ann Surg Oncol; 2007 Feb;14(2):810-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of disseminated tumor cells in liver biopsies of colorectal cancer patients is not associated with a worse prognosis.
  • BACKGROUND: Liver metastases occur frequently in colorectal cancer and are probably caused by disseminated tumor cells having been trapped in the liver.
  • The prognostic significance of hematogenous tumor cell dissemination has already been demonstrated for blood and bone marrow of patients with colorectal cancer.
  • The aim of this study was to investigate the frequency and prognostic significance of disseminated tumor cells in liver biopsies of colorectal cancer patients.
  • METHODS: Liver biopsies from 100 patients with UICC stage I-III colorectal cancer were taken prospectively during resection of the primary tumor.
  • Liver biopsies obtained from 16 patients with benign gastrointestinal diseases served as negative controls.
  • RESULTS: Disseminated tumor cells were detected in liver samples of 10/100 (10%) patients with UICC stage I-III colorectal cancer.
  • Liver specimens from all seven patients with liver cirrhosis were CK 20-positive, whereas 16 patients with other benign gastrointestinal diseases were all CK 20-negative.
  • There was no correlation between tumor cell detection in liver biopsies and survival of the patients.
  • CONCLUSIONS: This study demonstrates that detection of disseminated tumor cells in liver samples from patients with UICC stage I-III colorectal cancer has no prognostic influence.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver / pathology. Liver Neoplasms / secondary. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Aged. Biopsy. Female. Humans. Keratin-20 / analysis. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies


92. Szajda SD, Jankowska A, Zwierz K: Carbohydrate markers in colon carcinoma. Dis Markers; 2008;25(4-5):233-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spontaneously mutated multiple oncogenes and/or tumor suppressor genes in colon epithelial cell and its progeny, may cause proliferation out of control and create benign colon neoplasm (colon polyp).
  • If additional mutations involve genes responsible for cell adhesion and movement, aberrant epithelial cells may become malignant (colon cancer) and invade surrounding and remote tissues, creating secondary tumors called metastases.
  • Incidence of colorectal cancer dramatically increases at 50-65 year of age.
  • In Europe in 2006 colorectal cancer consisted 12.9% of all cancers and caused 207,400 deaths.
  • To laboratory detection and monitoring of colon cancer are used tumor markers.
  • Tumor markers are substances produced by the body in response to cancer, or by cancer tissue itself.
  • A glycobiological approach to diagnosis and treatment of colorectal cancer should be directed to detection changes in glycosylation accompanying every step of colon cancer progression, and correlation between changes in glycosylation and tumor progression.
  • [MeSH-major] Carbohydrates / chemistry. Carcinoma / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Cadherins / chemistry. Cell Adhesion. Disease Progression. Epithelial Cells / metabolism. Glycoproteins / chemistry. Glycoproteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. Polysaccharides / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126967.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Mucins; 0 / Polysaccharides
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC3827819
  •  go-up   go-down


93. Cui M, Wang S, Ye YJ, Cui ZR, Ke Y: [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer]. Zhonghua Yi Xue Za Zhi; 2007 Jan 2;87(1):16-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer].
  • OBJECTIVE: To analyze the effect of tumor burden on the differentiation of T1 and T2 cells and its implication in patients with colorectal cancer.
  • METHODS: Peripheral venous blood samples were obtained from 20 patients with primary colorectal cancer before and 7 days after the operation, radical operation in 17 patients and palliative resection in 3 patients.
  • Twenty sex and age-matched patients with benign diseases treated in the same period were used as controls.
  • RESULTS: At the time of diagnosis, the percentage of T1 and T2 cells in the peripheral lymphocytes of the case group was lower significantly than that of the control group (P = 0.006, and P = 0.017).
  • After getting rid of the tumor burden, the percentage of T1 cells increased, however, not significantly (P > 0.05).
  • The percentages of T1 cell of the patients with the tumor > or = 5 cm and of the patients with poorly differentiated tumors were significantly lower than those of the patients with the tumor < 5 cm and of the patients with well or moderately differentiated tumors (P = 0.064, and P = 0.072).
  • The percentage of T1 cells in the patients with lymph node metastasis and stage III approximately IV tumor were lower significantly than those of the patients without lymph node metastasis and those with stage I approximately II tumor (P = 0.033 and P = 0.033).
  • No significant differences were found between the population of T1 cells and such factors as tumor size, serosa invasion, and distant metastasis.
  • CONCLUSION: Tumor load suppresses the differentiation of T1 and T2 cells in the patients with colorectal cancer significantly, and may be an important factor in the development of immunosuppression.
  • After getting rid of the tumor burden, the percentages of T1 and T2 increase in a short time, and the immunologic function is improved.
  • Determination of T1 may be helpful to indicate the prognosis of colorectal cancer.
  • [MeSH-major] Cell Differentiation / immunology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. T-Lymphocytes / cytology
  • [MeSH-minor] Aged. CD4-Positive T-Lymphocytes / cytology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / cytology. CD8-Positive T-Lymphocytes / immunology. Female. Flow Cytometry. Humans. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Male. Middle Aged. Neoplasm Staging. Tumor Burden

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403305.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


94. Gottwald L, Korczyński J, Góra E, Bieńkiewicz A: [Adnexal tumors after surgical treatment of colorectal cancer]. Ginekol Pol; 2008 Apr;79(4):259-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adnexal tumors after surgical treatment of colorectal cancer].
  • OBJECTIVE: The risk of metastatic ovarian tumor is significantly higher in case of women with a history of colorectal cancer.
  • DESIGN: The purpose of the study was to evaluate the clinical presentation and histopathology of adnexal tumors in case of female patients with a history of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: A retrospective study on 13 women (each with a history of colorectal carcinoma, operated due to adnexal tumor between 2004 and 2007), has been conducted.
  • Subject characteristics, ultrasound, CT, serum tumor markers levels, histopathology and findings at surgery were analyzed.
  • RESULTS: Time distance between colorectal cancer surgery and ovarian tumor operation - measured in months -was shorter in cases of malignant neoplasms (10.13 +/- 3.98) than in benign tumors (26.2 +/- 19.37).
  • Ultrasound examination showed solid-cystic adnexal tumors in 8 malignant cases, and ovarian cysts in 5 benign conditions.
  • Unilateral adnexectomy only took place in one case of benign tumor and in one case of disseminated neoplasmatic disease.
  • CONCLUSIONS: When evaluating a patient with an adnexal tumor, a history of malignancy strongly suggests a metastatic nature.
  • The use of ultrasound associated with plasma levels of Ca 125, Ca 19-9 and CEA, represents a useful method of preoperative assessment of ovarian tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Retrospective Studies. Risk Assessment. Ultrasonography, Doppler, Color / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592863.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


95. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • The purpose of this study was to evaluate the incidence and clinicopathological features of extrapancreatic tumors associated with IPMN.
  • These patients were examined for the development of extrapancreatic tumors.
  • RESULTS: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • Gastric adenocarcinoma (3 patients, 23%) and colorectal carcinoma (3 patients, 23%) were the most common neoplasms.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • CONCLUSIONS: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasms.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


96. He Q, Zhang P, Zou L, Li H, Wang X, Zhou S, Fornander T, Skog S: Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep; 2005 Oct;14(4):1013-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity.
  • Activity of thymidine kinase 1 in serum (STK) is a useful marker for leukaemia and lymphoma, but not for solid tumors.
  • We investigate thymidine kinase 1 concentration in serum (S-TK1) as a potential tumor marker.
  • S-TK1 concentration and STK activity levels were determined in 9 human malignant diseases (breast, gastric, rectal, colorectal, lung, brain cancer, hepatoma, lymphoma, leukaemia) and in benign and non-cancerous diseases, representing 850 preoperative cases.
  • S-TK1 concentrations and STK activity levels in preoperative malignant patients were significantly higher than in healthy individuals, in patients with benign tumors and in those with non-cancerous diseases.
  • Significant correlations between concentration and activity level were only found in healthy individuals, in patients with benign tumors, and in some patients with malignancies, i.e. leukaemia, and breast and gastric cancers.
  • We conclude that S-TK1 concentration is a more sensitive tumor marker in solid malignancies than is STK activity.
  • [MeSH-major] Biomarkers, Tumor. Neoplasms / blood. Neoplasms / diagnosis. Thymidine Kinase / blood
  • [MeSH-minor] Breast Neoplasms / pathology. Cell Line, Tumor. Cell Proliferation. Dose-Response Relationship, Drug. Female. Humans. Male. Neoplasm Staging. Radioimmunoassay / methods. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16142366.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.1.21 / Thymidine Kinase; EC 2.7.1.21 / thymidine kinase 1
  •  go-up   go-down


97. Barnetson RA, Cartwright N, van Vliet A, Haq N, Drew K, Farrington S, Williams N, Warner J, Campbell H, Porteous ME, Dunlop MG: Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer. Hum Mutat; 2008 Mar;29(3):367-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Classification of ambiguous mutations in DNA mismatch repair genes identified in a population-based study of colorectal cancer.
  • Identification of germline mutations in DNA mismatch repair genes in colorectal cancer probands without an extensive family history can be problematic when ascribing relevance to cancer causation.
  • We undertook a structured assessment of the disease-causing potential of sequence variants identified in a prospective, population-based study of 932 colorectal cancer patients, diagnosed at <55 years of age.
  • Pathogenicity was assessed by determining segregation in families, allele frequency in large numbers of unaffected controls, effect on mRNA for putative splice-site mutations, effect on protein function by bioinformatic analysis and tumor microsatellite instability (MSI) status and DNA mismatch repair protein expression by immunohistochemistry.
  • MLH1 c.200G>A p.G67E, MLH1 c.2041G>A p.A681T, and MSH2 c.2634+5G>C were categorized as pathogenic through assimilation of all available data, while 14 variants were categorized as benign (seven MLH1, three MSH2, and four MSH6).
  • These findings support a causal link with colorectal cancer for several DNA mismatch repair gene variants.
  • [MeSH-major] Colorectal Neoplasms / genetics. DNA Mismatch Repair. DNA Repair / genetics. Germ-Line Mutation
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / genetics. Alleles. Base Sequence. Case-Control Studies. DNA, Neoplasm / genetics. DNA-Binding Proteins / genetics. Female. Gene Frequency. Humans. Male. Middle Aged. MutL Protein Homolog 1. MutS Homolog 2 Protein / genetics. Nuclear Proteins / genetics. Prospective Studies. Scotland

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Pharmacogenomics Knowledge Base. meta-databases - Pharmacogenomic Annotation 827853391 for PMID:18033691 [PharmGKB] .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18033691.001).
  • [ISSN] 1098-1004
  • [Journal-full-title] Human mutation
  • [ISO-abbreviation] Hum. Mutat.
  • [Language] eng
  • [Grant] United Kingdom / Chief Scientist Office / / CZB/4/449; United Kingdom / Medical Research Council / / MC/ U127527198
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / G-T mismatch-binding protein; 0 / MLH1 protein, human; 0 / Nuclear Proteins; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutL Protein Homolog 1; EC 3.6.1.3 / MutS Homolog 2 Protein
  •  go-up   go-down


98. Whitehouse PA, Tilney HS, Armitage JN, Simson JN: Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas. Colorectal Dis; 2006 Nov;8(9):795-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas.
  • OBJECTIVE: Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for excision of selected benign and malignant rectal neoplasms.
  • It is considered a safe and effective treatment but recurrence rates of 1-13% are reported for benign lesions.
  • The aim of this study was to assess risk factors for local recurrence of benign rectal lesions and to evaluate mortality and morbidity following TEM.
  • METHOD: Data were prospectively collected from all patients undergoing TEM for benign adenomas from January 1998 to March 2005.
  • CONCLUSION: TEM is a safe and effective treatment for benign rectal adenomas.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Microsurgery / methods. Neoplasm Recurrence, Local. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2006 Nov;8(9):731-2 [17032317.001]
  • (PMID = 17032328.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


99. Hong R, Lim SC: Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report. World J Gastroenterol; 2009 Jul 14;15(26):3315-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report.
  • A granular cell tumor (GCT) is a benign neoplasm of unclear histogenesis that is generally believed to be of nerve sheath origin.
  • In addition to the tumor, endoscopic examination revealed the presence of a 5-mm-polyp in the descending colon and multiple tiny polyps in the sigmoid colon and rectum.
  • Histological examination demonstrated a cecal tumor 1.5 cm x 1.0 cm x 0.7 cm with a hard consistency; in cut sections, mixed cells with yellowish and whitish portions were seen.
  • The tumor was located between the mucosa and subserosa, and was composed of plump histiocyte-like tumor cells with abundant granular eosinophilic cytoplasm, which were immunoreactive for S-100 protein, vimentin, neuron-specific enolase, inhibin-alpha and calretinin.
  • The tumor showed extensive hyalinization and focal dystrophic calcification.
  • Extensive hyalinization and calcification showing involution of tumor cells suggest benign clinical behavior of GCT.
  • [MeSH-major] Calcinosis / pathology. Cecum / pathology. Granular Cell Tumor / pathology. Hyalin / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Calbindin 2. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Humans. Male. Middle Aged. Phosphopyruvate Hydratase. S100 Calcium Binding Protein G. S100 Proteins. Vimentin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ugeskr Laeger. 2006 May 22;168(21):2080-1 [16768929.001]
  • [Cites] J Oral Pathol Med. 1997 Apr;26(4):164-9 [9176790.001]
  • [Cites] J Craniofac Surg. 2008 Nov;19(6):1691-4 [19098584.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):150-9 [19192059.001]
  • [Cites] J Gastroenterol. 2000;35(8):631-4 [10955603.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1200-3 [11688581.001]
  • [Cites] J Gastroenterol. 2003;38(4):385-9 [12743780.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2452-4 [15285042.001]
  • [Cites] Mt Sinai J Med. 1979 Mar-Apr;46(2):195-8 [220528.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Apr;65(4):427-35 [2834681.001]
  • [Cites] Am J Gastroenterol. 1989 Jun;84(6):656-9 [2543214.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):311-5 [8424442.001]
  • [Cites] Am J Gastroenterol. 1993 Oct;88(10):1785-7 [8213726.001]
  • [Cites] Pathologica. 1995 Apr;87(2):175-8 [8532413.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Dec;80(6):687-97 [8680977.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Jan;94(1):27-32 [9028140.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):73-4 [18386247.001]
  • (PMID = 19598311.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Vimentin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Other-IDs] NLM/ PMC2710791
  •  go-up   go-down


100. Bui MM, Draper NL, Dessureault S, Nasir NA, Cooper H, Nasir A, Coppola D: Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature. Clin Colorectal Cancer; 2010 Jul;9(3):179-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whether AHE is a reactive process or a neoplastic process (either a benign vascular neoplasm or a T-cell lymphoproliferative disorder) is still under debate.
  • [MeSH-major] Angiolymphoid Hyperplasia with Eosinophilia / pathology. Colonic Diseases / pathology. Colonic Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Head and Neck Neoplasms / complications. Hemangioma / complications. Humans. Ovarian Neoplasms / complications